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Daniel Strakis Albrecht 
ASSESSMENT OF THE DOPAMINE SYSTEM IN ADDICTION USING POSITRON 
EMISSION TOMOGRAPHY 
 
 Drug addiction is a behavioral disorder characterized by impulsive behavior and 
continued intake of drug in the face of adverse consequences.  Millions of people suffer 
the financial and social consequences of addiction, and yet many of the current 
therapies for addiction treatment have limited efficacy.  Therefore, there is a critical need 
to characterize the neurobiological substrates of addiction in order to formulate better 
treatment options.  In the first chapter, the striatal dopamine system is interrogated with 
[11C]raclopride PET to assess differences between chronic cannabis users and healthy 
controls.  The results of this chapter indicate that chronic cannabis use is not associated 
with a reduction in striatal D2/D3 receptor availability, unlike many other drugs of abuse.  
Additionally, recent cannabis consumption in chronic users was negatively correlated 
with D2/D3 receptor availability.  Chapter 2 describes a retrospective analysis in which 
striatal D2/D3 receptor availability is compared between three groups of alcohol-drinking 
and tobacco-smoking subjects:  nontreatment-seeking alcoholic smokers, social-drinking 
smokers, and social-drinking non-smokers.  Results showed that smokers had reduced 
D2/D3 receptor availability throughout the striatum, independent of drinking status.  The 
results of the first two chapters suggest that some combustion product of marijuana and 
tobacco smoke may have an effect on striatal dopamine concentration.  Furthermore, 
they serve to highlight the effectiveness of using baseline PET imaging to characterize 
dopamine dysfunction in addictions.  The final chapter explores the use of [18F]fallypride 
PET in a proof-of-concept study to determine whether changes in cortical dopamine can 
be detected during a response inhibition task.  We were able to detect several cortical 
regions of significant dopamine changes in response to the task, and the amount of 
change in three regions was significantly associated with task performance.  Overall, the 
results of Chapter 3 validate the use of [18F]fallypride PET to detect cortical dopamine 
changes during a impulse control task.  In summary, the results reported in the current 
document demonstrate the effectiveness of PET imaging as a tool for probing resting 
and activated dopamine systems in addiction.  Future studies will expand on these 
results, and incorporate additional methods to further elucidate the neurobiology of 
addiction.          
Gary D. Hutchins, PhD, Chair 
vii 
 
Table of Contents 
 
List of Tables viii    
List of Figures ix 
List of Abbreviations x 
Introduction 1 
Chapter 1:  Baseline striatal D2/D3 receptor availability in chronic cannabis users  
Introduction 19 
Methods 20 
Results 24 
Discussion 26 
Chapter 2:  Effects of cigarette smoking on striatal D2/D3 receptor availability in   
alcoholics and social drinkers 
Introduction 33 
Methods 34 
Results 37 
Discussion 42 
Chapter 3:  Cortical dopamine release during a behavioral response inhibition task  
Introduction 49 
Methods 51 
Results 55 
Discussion 61 
Summary 64 
Future Directions 68 
References 71 
Curriculum Vitae 
 
viii 
 
List of Tables 
 
Table 1.  Subject demographics and drug-use characteristics (Chapter 1) 25  
  
Table 2.  Region of interest analysis:  comparison of striatal binding 27 
potential between chronic cannabis users and healthy controls (Chapter 1)   
 
Table 3.  Subject characteristics (Chapter 2) 38 
 
Table 4.  Binding potential values (BPND), all groups (Chapter 2) 39 
 
Table 5.  Binding potential values (BPND) from the region of interest (ROI)  41 
analysis, stratified by smoking status (Chapter 2) 
 
Table 6.  Region of interest (ROI) volumes from all groups (Chapter 2) 43 
 
Table 7.  Performance on the “Go” attention task and Stop Signal task  56 
(Chapter 3) 
 
Table 8.  Voxel-wise results of changes in dopamine (DA) during the SST  57 
(Chapter 3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
List of Figures 
 
Figure 1.  Voxel-wise correlations between urine THC-COOH/Cr with RAC  28 
BPND in cannabis users (Chapter 1) 
 
Figure 2.  Voxel-wise correlations between self-reported average intake per 29 
day and RAC BPND in cannabis users (Chapter 1) 
 
Figure 3.  Individual BPND data from the right pre-commissural dorsal  40 
putamen (R-pre-DPU), by group (Chapter 2) 
 
Figure 4.  Whole-brain voxel-wise paired t-test comparing BPND between  59 
baseline “Go” and SST scan conditions, DA goes up (Chapter 3) 
 
Figure 5.  Whole-brain voxel-wise paired t-test comparing BPND between  60 
baseline “Go” and SST scan conditions, DA goes down (Chapter 3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
 
List of Abbreviations 
 
∆BPND  change in binding potential 
ºC  degrees celcius 
3T  3 Tesla 
AA  African American 
ACC  anterior cingulate cortex 
AI  anterior insula 
ANOVA  analysis of variance 
A-O  action-outcome 
ATM  atomoxetine 
AUC  area under the curve 
AUDIT  Alcohol Use Disorder Identification Test 
BAES  Biphasic Alcohol Effects Scale 
BIS-11  Barratt Impulsivity Scale 
BOLD  blood oxygen level dependent 
BPND  binding potential 
BrAC  breath alcohol 
C  Caucasian 
CAN  cannabis 
CB1  cannabinoid type 1 
cc  cubic centimeter 
CIWA-Ar  Clinical Withdrawal Assessment for Alcohol, Revised 
COMT  catechol-O-methyltransferase 
CON  control 
Cr  creatinine 
CWS  Cigarette Withdrawal Scale 
DA  dopamine 
Daergic  dopaminergic 
DCA  dorsal caudate 
dL  deciliter 
DLS  dorsolateral striatum 
DMS  dorsomedial striatum 
xi 
 
DSM-IV  Diagnostic and Statistical Manual of Mental Disorders IV 
DTI  diffusion tensor imaging 
EtOH  ethanol 
FAL  [18F]fallypride 
FLU  α-flupenthixol 
fMRI  functional magnetic resonance imaging 
FSCV  fast-scan cyclic voltammetry 
GC-MS  gas chromatography-mass spectrometry 
GP  globus pallidus 
I  Asian-Indian American 
IFC  inferior frontal cortex 
IFG  inferior frontal gyrus 
IPL  inferior parietal lobule 
ITG  inferior temporal gyrus 
IV  intravenous 
kg  kilogram 
L  left 
LSD  least square difference 
MAO-A  monoamine oxidase A 
MAO-B  monoamine oxidase B 
MBq  megabecquerel 
mCi  millicurie 
MFG  middle frontal gyrus 
mg  milligram 
mL  milliliter 
mm  millimeter 
MNI  Montreal Neurological Institute 
MP  methylphenidate 
MP-RAGE  magnetized prepared rapid gradient echo  
MRI  magnetic resonance imaging 
MRTM  multilinear reference tissue model 
N/A  not applicable 
NAcc  nucleus accumbens  
NE  norepinephrine 
xii 
 
ng  nanogram 
NHL  Non-Hispanic Latino 
NIfTI  Neuroimaging Informatics Technology Initiative 
nmol  nanomole 
NTS-S  nontreatment-seeking smokers 
OFC  orbitofrontal cortex 
OH-THC  11-hydroxy-THC 
PAS  Perceptual Aberration Scale 
PET  positron emission tomography 
PFC  prefrontal cortex 
postDCA  postcommissural dorsal caudate 
postDPU  postcommissural dorsal putamen 
preDCA  precommissural dorsal caudate 
preDPU  precommissural dorsal putamen 
pre-SMA  presupplementary motor area 
PUT  putamen 
QC  quality control sample 
R  right 
RAC  [11C]raclopride 
rCBF  regional cerebral blood flow 
ROI  region of interest 
RS-fMRI  resting state fMRI 
RT  reaction time 
SCID  Structured Clinical Diagnostic Interview for DSM-IV Disorders 
SD  standard deviation 
SD-NS  social-drinking non-smokers 
SD-S  social-drinking smokers 
SFG  superior frontal gyrus 
SMA  supplementary motor area 
SMG  supramarginal gyrus 
SN  substantia nigra 
SPECT  single photon emission computed tomography 
SPM  Statistical Parametric Mapping 
SPQ  Schizotypal Personality Questionnaire 
xiii 
 
S-R  stimulus-response 
SSAGA  Semi-Structured Assessment for the Genetics of Alcoholism 
SSD  stop signal delay 
SSRT  stop signal reaction time 
SST  stop signal task 
STG  superior temporal gyrus 
STN  subthalamic nucleus 
THC  ∆9-tetrahydrocannabinol  
THC-COOH  11-nor-∆9-THC-9-carboxylic acid 
TLFB  Time Line Follow Back 
TPQ  Tridimensional Personality Questionnaire 
VST  ventral striatum 
VTA  ventral tegmental area 
 
 
 
 
1 
 
Introduction 
 
 Drug addiction is a behavioral disorder characterized by impulsive behavior and 
continued intake of drugs in the face of adverse consequences.  Substance abuse is a 
ubiquitous global phenomenon.  In 2011, in the U.S. alone, 38 million people age 12+ 
reported illicit drugs use, 81 million reported tobacco use, and 168 million reported 
alcohol use (Samhsa, 2011).  However, only a relatively small proportion of people who 
engage in recreational substance use will progress to addiction.  In 2011, 11.2 million 
Americans met DSM-IV criteria for alcohol or illicit drug dependence, and 32 million met 
criteria for nicotine dependence (Samhsa, 2011).  The economic impact from these 
addictions is staggering; estimates have placed the annual economic cost of alcohol, 
tobacco, and illicit drug abuse to society in the U.S. at 191.6, 167.8, and 151.4 billion 
dollars, respectively (Fellows, 2002; Harwood, 2001; Harwood, 2000).  The impact of 
addictions on health care is similarly massive.  A comprehensive study of the global 
health burden from addictions reported that alcohol and tobacco were each responsible 
for 4% of the global disease burden (as measured by disability adjusted life years), and 
illicit drugs were responsible for 0.8% of the burden (Rehm, 2006).     
 One characteristic shared by many addicts is the inability to abstain from 
substance abuse, despite a desire to quit.  The vast majority of addicted individuals will 
attempt, often unsuccessfully, to discontinue substance abuse at some point during their 
use period.  There is a high likelihood of relapse during a period of attempted 
abstinence, and relapse rates are similar among the various substances of abuse (Hunt, 
1971).  Relapse rates average around 80% for alcohol (Miller, 1996); 95% for tobacco 
(Hughes, 2004); and 85% for heroin (Darke, 2005).  There are many different treatment 
methods for addiction, and most fall into the categories of either behavioral or 
pharmacological therapies (Dutra, 2008; O'brien, 2006).  Even though substantial 
resources have gone into developing and optimizing new treatments, efficacies remain 
modest.  A better understanding of the neurobiology of addiction would provide a 
framework for the development of more effective therapies.  Therefore, there is a critical 
need to elucidate the neurobiological substrates underlying the process of addiction.       
 
Dopaminergic Circuitry and Signaling  
Dopamine (DA) is a monoamine neurotransmitter that operates on a wide variety 
of brain functions.  The primary DA-producing nuclei in the brain are the ventral 
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tegmental area (VTA) and substantia nigra (SN), located in the midbrain (Swanson, 
1982).  Three main afferents arise from the VTA/SN:  the mesolimbic circuit, which 
originates from VTA neurons and projects to the ventral striatum; the nigrostriatal circuit, 
which originates from the SN and projects to more dorsal striatal regions; and the 
mesocortical circuit, which originates from the VTA and projects to the frontal cortices.  
Projections from the midbrain to the striatum are arranged in an inverted topography, 
such that the dorsal most nuclei project more ventrally, and the ventral most nuclei 
project more dorsally (Fallon, 1978)  Although early tracing studies seemed to indicate 
that these circuits were distinct in their terminal projection fields, more recent research 
has uncovered a substantial amount of overlap in VTA/SN projection fields (Lynd-Balta, 
1994a, 1994b).  Overlapping projection areas allow for greater modulation of 
dopaminergic (DAergic) signaling, as neurotransmission is under control of more than 
one region.  Furthermore, for each projection from the midbrain nuclei to the striatum, 
there are two reciprocal projections back to the midbrain:  one that forms a “closed” loop 
with the originating midbrain projection area, and one that synapses in a midbrain region 
laterally to the origin (Haber, 2000).  In this manner, activity in the ventral striatum can 
affect activity in the dorsal striatum, although there are no direct connections between 
the regions.  Similarly to midbrain innervation of the striatum, corticostriatal projections 
are also arranged topographically, and the projection fields of distinct cortical regions 
overlap in their striatal terminals (Haber, 2006).    
DA neurons of the SN/VTA display two different types of firing patterns:  tonic 
and phasic.  Phasic and tonic DA signaling can be modulated differently, depending on 
the type of afferent input (Floresco, 2003).  Neurons in a freely moving animal can switch 
between tonic and phasic signaling, and firing rates have been shown to increase in 
response to environmental salient stimuli (Hyland, 2002)  Importantly, DA-dependent 
behaviors can be differentially regulated by tonic or phasic signaling (Zweifel, 2009).  In 
this elegant study by Zweifel et al., phasic DA signaling was selectively ablated in order 
to assess regulation of behavior by phasic or tonic DAergic transmission.  Disruption of 
the phasic DA transients impaired behaviors that involved learned associations of 
environmental cues with salient events.  Many other behaviors were unaffected, 
presumably because of the functionally intact tonic DA signaling.  In this manner, drugs 
that effect phasic and tonic DA signaling disparately may have correspondingly different 
effects on behavioral outcome.        
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DA binds to two different classes of G-protein coupled receptors in the brain:  D1-
like [D1 and D5], and D2-like [D2, D3, D4] (Vallone, 2000).  DA receptors are widely 
expressed throughout the brain, with the highest expression levels in the striatum 
(containing the caudate, putamen, and nucleus accumbens), olfactory tubercle, 
amygdala, and SN/VTA (Jackson, 1994).  Receptor expression is relatively moderate in 
other regions, i.e. cerebral cortex, hippocampus, thalamus, and cerebellum.  It is no 
coincidence that many of these structures are heavily involved in the neurobiology of 
addiction.  DA modulates a wide array of addictive processes via complicated signaling 
between these structures.            
 
Involvement of DA throughout Addiction 
 One of the initial findings suggesting the involvement of DA in addiction was the 
ability of drugs of abuse to increase extracellular DA concentrations in the nucleus 
accumbens of rats (Di Chiara, 1988b).  This pioneer study collected dialysate from rat 
nucleus accumbens (NAcc) and dorsal caudate (DCA) during investigator-administered 
drug challenges with both common drugs of abuse (opiates, ethanol, nicotine, 
amphetamine, and cocaine) and non-abused drugs (haloperidol, imipramine, atropine, 
and diphenydramine).  DA release varied across substances; the non-abused drugs 
imipramine, atropine, and diphenydramine elicited no detectable DA release in either 
brain region; haloperidol, a neuroleptic with DA antagonist actions, increased basal DA 
equally in the NAcc and DCA; all of the abused drugs also increased extracellular DA 
concentrations in both regions, but the magnitude of NAcc release was significantly 
higher than release in the DCA.  Subsequent studies replicated these findings and 
extended them to include cannabinoids (Kalivas, 1990; Tanda, 1997a; Yoshimoto, 
1992).   
While studies of investigator-administered drugs are useful, an animal model of 
addiction that incorporates voluntary substance intake is more closely related to the 
human condition.  Many studies of drug-induced DA release incorporate a self-
administration paradigm, where an animal is trained to perform a specific type of 
response to earn access to the drug (for a comprehensive review, see Gardner, 2000).  
Self-administration studies have reported DA release in the NAcc during voluntary intake 
of cocaine, ethanol, heroin, and cannabinoids (Di Ciano, 1995; Fadda, 2006a; Pettit, 
1989; Weiss, 1993), similar to studies of investigator-administered drugs.  For the sake 
of brevity, this discussion of drug-induced DA release has been presented in a simplistic 
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light, as variables such as cellular mechanisms and timing of DA release are outside the 
scope of the current discussion.  Together, results from these studies led to the 
conclusion that all drugs of abuse share the characteristic of preferentially increasing 
extracellular DA in the NAcc, at least during initiation of use (the time course of DA 
signaling during addiction will be discussed in the next section).   
It was originally thought that drug-induced DA release in the ventral striatum 
(VST) was directly responsible for the subjective euphoria associated with drugs of 
abuse (Wise, 1978), but the role of DA in reward is likely more complicated.  A 
sophisticated series of electrophysiological studies helped shed light on this issue 
(Schultz, 1997).  When animals were presented with an unpredicted rewarding stimulus 
that was temporally paired with a visual or audio cue, DA neurons responded by burst-
firing.  This increased firing presumably increased extracellular DA concentrations in the 
NAcc, as might have been predicted by the drug administration studies above.  
However, after repeated pairing of cue and reward, the DA neurons began firing after 
presentation of the conditioned cue, but not during presentation of the reward.  This shift 
in firing patterns indicated that DA neurons were not responding to the reward itself, but 
rather to some learned association between the cue and reward.  Additionally, the DA 
neurons displayed decreased firing if the conditioned cue was presented, but no reward 
delivered.  The authors deemed this a “prediction error” signal.  Although a discussion of 
the prediction error hypothesis is outside the scope of this document, the role of DA in 
cue conditioning is an important one, as is the concept of temporally dynamic DA 
signaling.   
 While it is generally accepted that most drugs of abuse share the ability to 
acutely increase DA concentrations in the ventral striatum, this is not sufficient to cause 
addiction.  Indeed, only an estimated 2.9% of individuals that try addictive substances in 
their life will proceed to addiction (Grant, 1998).  Therefore, there must be additional 
neurobiological factors that contribute to the progression to addiction.  It has been 
suggested that substance intake begins as a goal-directed behavior (mediated by action-
outcome (A-O) associations), that progresses to habitual substance intake (mediated by 
stimulus-response (S-R) associations), over the course of addiction (Everitt, 2001).  
Goal-directed (A-O) behaviors are governed by an associative representation of the 
contingency between the action and the outcome.  Relative to human substance intake, 
individuals initiate drug taking behavior because of the association between the 
substance and its rewarding effects.  In contrast, habitual (S-R) behaviors are simple 
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response habits that are triggered by environmental stimuli, whereby presentation of a 
stimulus will reliably and automatically elicit a response, even without contingent 
presentation of a reward.  Relative to human drug use, this is akin to the initiation of 
drug-seeking behavior following exposure to a drug-associated stimulus.  Based on 
these concepts, it is possible to experimentally assess whether a behavior is more under 
goal-oriented or habitual control.  Because A-O behaviors depend on the relationship 
between action and reward outcome, changing that association will lead to behavioral 
changes (e.g. devaluing the reward will lead to fewer lever presses in the drug-seeking 
stage) (Adams, 1981).  Conversely, if a behavior is habitual (S-R), then devaluing the 
relationship between action and reward outcome will not affect drug-seeking behavior.  
Using this devaluation paradigm, researchers have been able to gain important 
information about the progression of addiction from the initiation of drug-taking to 
compulsive drug abuse.   
 Evidence indicates that initial goal-directed behavior is mediated largely by VST 
(NAcc) and dorsomedial striatum (DMS), whereas habitual, compulsive behavior is 
mediated more so by dorsolateral striatum (DLS).  Inactivation of the NAcc (Corbit, 2001; 
Kelley, 1997) or DMS (Yin, 2005) impairs instrumental behavior under action-outcome 
control, as rewards become insensitive to devaluation.  Conversely, DLS-lesioning 
impairs habit formation, and shifts behavior towards more action-outcome control (Yin, 
2005).  Furthermore, recent studies suggest that the shift from goal-oriented behavior to 
habitual behavior throughout the course of addiction is accompanied by a shift in 
behavioral control from VST to DMS to DLS.  Initial drug use is under control of goal-
directed behavior, which is supported by animal models of reward devaluation in early 
cocaine and ethanol seeking (Corbit, 2012; Olmstead, 2001; Samson, 2004; Zapata, 
2010), [although there is some evidence that different types of instrumental training 
produce habitual behavior prematurely (Dickinson, 2002; Mangieri, 2012; Murray, 
2012)].  However, after extended training periods, drug-seeking cannot be attenuated by 
reward devaluation, indicating a transition from action-outcome to habitual responding 
(Corbit, 2012; Zapata, 2010).  Inactivation of the DMS during acquisition of early alcohol-
seeking impairs goal-oriented behavior (Corbit, 2012).  Conversely, when drug-seeking 
is under habitual control after extensive training, inactivation of the DMS has no effect, 
whereas DLS inactivation alters habitual responding and reverts behavior to goal-
directed control, reinstating sensitivity to reward devaluation (Corbit, 2012; Zapata, 
2010).   
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Importantly, this signaling shift between striatal regions is regulated, in part, by 
DA.  During acquisition of early cocaine-seeking, intra-cranial infusion of α-flupenthixol 
(FLU; a non-selective DA antagonist) into the DMS, but not DLS, disrupted goal-directed 
cocaine-seeking (Murray, 2012).  Conversely, intra-cranial infusion of FLU into the DLS, 
but not DMS, caused aberrant drug-seeking after habitual responding had been 
established (Belin, 2008; Murray, 2012).  Furthermore, the transition from ventral to 
dorsal striatal areas during the progression of drug use is dependent on serial 
connectivity linking the ventral to dorsal striatum (Belin, 2008; Willuhn, 2012).  Belin et 
al. (2008) showed that a unilateral NAcc lesion attenuated drug-seeking to the same 
degree as intra-DLS FLU infusions, indicating that intact NAcc signaling is necessary for 
the development of DLS-controlled habitual behavior.  Using fast-scan cyclic 
voltammetry (FSCV), Willuhn et al. (2012) examined phasic DA signaling during 
progression of cocaine self-administration that was paired with conditioned stimuli.  They 
replicated the cocaine-induced phasic DA release in the VST, and demonstrated that the 
DA release gradually decreased in magnitude over three weeks.  In an opposite manner, 
DA release in the DLS was absent during the acquisition of cocaine intake, but 
significantly increased over the three weeks.  The VST was then lesioned unilaterally, 
which left DA signaling intact in the contralateral DLS.  However, DA transients in the 
DLS ipsilateral to the VST lesion were completely ablated, and absent throughout three 
weeks of cocaine use.  Based on this evidence, the ventral to dorsal shift in locus of 
behavioral control is thought to be dependent on the spiraling connections between 
ventral and dorsal striatum (Haber, 2000).  Taken together, the above studies strongly 
advance the idea that initial involvement of ventral striatal DA transmission in drug taking 
gradually progresses to more dorsal striatal regions, eventually resulting in compulsive 
drug intake.       
 
Human PET Imaging in Addiction  
Small animal studies, such as those mentioned in the above section, have been 
instrumental in understanding basic DAergic contributions to addiction.  However, 
addiction is a purely human affliction, and knowledge gained from small animal studies 
must be applied to the human condition with this caveat in mind.  Therefore, studies in 
human addicts are necessary to understand the role of DA in addiction in a more 
representative sample.  Because methods used to investigate neurochemistry in animals 
are far too invasive to be used ethically in humans (e.g. microdialysis, voltammetry), a 
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relatively non-invasive technique like positron emission tomography (PET) imaging 
offers unique advantages.  PET relies on systemic administration of radioligands (or 
radiotracers) that travel to the brain and bind to a molecule of interest.  Radioligands 
exist for several neurotransmitter systems, but this discussion will focus on DA receptor-
specific ligands.  Detection and localization of radioactive decay events by a PET 
scanner allows for in vivo characterization of human DA systems.  The most commonly 
used quantitative outcome in PET imaging is “binding potential” (BPND).  BPND is 
operationally defined as Bavail/KD, where Bavail refers to the density of receptors available 
to bind radioligand in vivo, and KD refers to the radioligand equilibrium dissociation 
constant (Innis, 2007).  BPND can be used to estimate DA receptor expression levels, but 
it can also be sensitive to levels of endogenous DA, as intrasynaptic and extracellular 
DA can compete with radioligands for binding at the receptor.  The susceptibility of 
radioligand binding to competition from endogenous DA varies widely for a number of 
radioligands (for a comprehensive review of this topic, see Yoder, 2011c).  The most 
commonly used radioligands for imaging the DA system are [11C]Raclopride (RAC), 
[18F]Fallypride (FAL), [11C]FLB, and [11C]PHNO, and many of the studies discussed in 
later sections employ these ligands.  It is important to note that the radiotracers listed 
above all specifically bind D2-like receptors.  There are many tracers that specifically 
target D1-like receptors (Laruelle, 2000), but the current discussion will focus on D2-
specific tracers.  Because some tracers are able to be displaced by endogenous DA, 
they can be used to detect DA release in vivo in response to some sort of challenge (e.g. 
pharmacologic, cognitive) (Dewey, 1991; Dewey, 1993).  Based on these properties, 
DA-specific radiotracers have been used to assess both differences in baseline D2 
receptor availability associated with addiction, as well as DA release in response to 
pharmacological drug effects, or conditioned properties associated with certain drugs.  
The following sections will include a critical review of studies that have employed these 
techniques to investigate DAergic function in substance addicts.  
 
Baseline Differences in Striatal D2 Receptors- association with Addiction 
 Since the initial development of PET radioligands specific to D2-like receptors, an 
immense amount of work has examined baseline striatal D2 receptor availability 
differences between addicted populations and healthy controls.  As will be discussed, 
there is a high degree of variability between study results.  However, this undertaking 
has yielded a great body of information regarding how DAergic systems are affected in 
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addiction.  Many of these studies reported lower D2 receptor availability in individuals 
that are dependent on or heavy users of alcohol (Heinz, 2004; Hietala, 1994; Martinez, 
2005; Rominger, 2012b; Volkow, 2007; Volkow, 1996), cocaine (Martinez, 2004; 
Martinez, 2011; Martinez, 2009; Volkow, 1997), opiates (Martinez, 2012; Wang, 1997a; 
Zijlstra, 2008), methamphetamines (Lee, 2009; Volkow, 2001a), and tobacco (Albrecht, 
2013; Busto, 2009; Fehr, 2008; Stokes, 2012), relative to healthy controls.  Conversely, 
no investigations of chronic cannabis users have reported any differences in striatal D2 
receptor availability between this population and healthy controls (Albrecht, 2012a; Sevy, 
2008b; Stokes, 2012; Urban, 2012b).   
Though this body of work and the accordance of results are impressive, there are 
a number of similar studies that reported contrary findings for certain drug classes.  
Using SPECT D2-binding ligands [123I]epidepride and [123I]IBZM, and PET ligands FAL 
and RAC, several groups reported no differences in striatal D2 receptor availability 
between alcoholics and controls (Albrecht, 2013; Guardia, 2000b; Repo, 1999b; 
Spreckelmeyer, 2011).  It is possible that some discrepancies result in part from the use 
of SPECT tracers (Guardia, 2000b; Repo, 1999b), whereas the studies reporting 
significant differences utilized mainly RAC and FAL.  However, another possible 
explanation lies in differential matching of control subjects.  Many studies of addicted 
populations exclude subjects for substance use, but often with the exception of tobacco 
cigarettes.  Because significant differences in D2 receptor availability have been 
associated with tobacco smoking (see above), it is possible that imbalances in smoking 
status between alcoholics and controls in some studies may have accounted for reports 
of lower D2 receptor availability in alcoholics (Heinz, 2004; Hietala, 1994; Rominger, 
2012b; Volkow, 2007; Volkow, 1996).  Interestingly, of the two studies that used FAL to 
estimate baseline D2 availability in alcoholics, the one that matched for smoking status in 
controls reported no effects (Spreckelmeyer, 2011), while the one that did not match for 
smoking status reported lower striatal FAL BPND in alcoholics (Rominger, 2012b).  
Although this point strongly supports careful matching of controls to addicted individuals, 
one investigation matched controls for smoking status and reported lower striatal D2 
availability in alcoholics (Martinez, 2005).  Only two studies in alcoholics have both used 
RAC and matched controls for smoking status, and reported contrasting results 
(Albrecht, 2013; Martinez, 2005).  Differences in alcoholic populations in these two 
studies, [nontreatment-seeking alcoholics in (Albrecht, 2013) and detoxified and 
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abstinent alcoholics in (detoxified and abstinent alcoholics in Martinez, 2005)], could 
potentially account for the discrepant results.   
 Similar to the story for alcohol, one group reported that tobacco-smoking subjects 
did not display lower striatal D2 receptor availability compared to non-smoking controls 
(Yang, 2006).  The main difference between the study by Yang et al. (2006) and those 
reporting positive results, is that the former study used SPECT and [123I]IBZM to 
estimate D2 availability.  It is possible that SPECT methodology may not be best suited 
for detecting effects of group (see above, Guardia, 2000b).   
Based on results from the above studies, there is a strong consensus that heavy 
abuse of psychostimulants (cocaine, methamphetamine), opiates, and tobacco (though 
some effects of tobacco may be sex-linked, Brown, 2012) is associated with lower 
striatal D2 receptor availability.  Chronic use of alcohol also appears to be associated 
with lower striatal D2 availability (Martinez, 2005), and this effect may be most apparent 
in severe alcoholism.  It is unclear whether lower striatal D2/D3 receptor availability 
occurs prior to the onset of substance abuse, or is a consequence of long-term abuse.  
There is some evidence to suggest that higher D2 receptor availability is protective in 
unaffected family members of alcoholics (Volkow, 2006a), but unfortunately cross-
sectional studies are ill equipped to distinguish this difference.  In contrast to other drugs 
of abuse, there have been no findings of lower striatal BPND in cannabis users.   
Investigations comparing striatal D2 receptor availability in addicted populations should 
incorporate careful matching of control subjects in the study design.   
                 
Drug-induced DA Release in Human Subjects 
 As discussed previously, an abundance of animal studies have confirmed that 
virtually every drug of abuse elicits increases in extracellular DA levels, but the evidence 
for DA release in response to certain drug classes is less conclusive in human studies.  
There is a consensus among many studies that psychostimulants (e.g. cocaine, 
amphetamine, methylphenidate) reliably increase striatal DA in both healthy controls and 
addicted populations (Cox, 2009; Drevets, 2001; Martinez, 2012; Martinez, 2003; 
Oswald, 2007; Schlaepfer, 1997; Urban, 2012b; Volkow, 2007).  Therefore, the following 
discussion will be limited to studies employing non-psychostimulant challenges.  
Because DA release in response to drug intake is thought to play an important role in the 
development and maintenance of addiction, studies of drug-induced DA release in 
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humans can yield critical information about the DAergic response to specific substances 
of abuse.       
 Several RAC PET studies have attempted to detect DA release in social-drinkers 
via an alcohol challenge, with varying results.  Four studies used oral alcohol in order to 
induce striatal DA release (Boileau, 2003; Salonen, 1997; Setiawan, 2013; Urban, 2010).  
All these studies, with the exception of Salonen et al. (1997), reported significant 
decreases in striatal RAC BPND, indicative of DA release in response to the alcohol.  
Specifically, Boileau et al. (2003) found DA release in the ventral striatum (VST) in six 
social-drinking males; Urban et al. (2010) reported significant DA release in all striatal 
regions in men, but only in VST and precommissural dorsal putamen (preDPU) in 
women; and Setiawan et al. (2013) found that the direction of DA change in response to 
alcohol was dependent on subjective response to intoxication, where high responders 
displayed decreased DA after alcohol and low responders displayed increased DA.  
Conversely, in four separate studies that utilized an IV alcohol challenge (Ramchandani, 
2011; Yoder, 2007; Yoder, 2005; Yoder, 2009), only one reported significant DA release 
in the VST, but only after alcohol delivered unexpectedly (Yoder, 2009).  Specifically, 
two studies from Yoder et al. (‘05, ‘07) found no group effect of alcohol on RAC BPND; 
Ramchandani et al. (2011) reported a significant effect of OPRM1 genotype on striatal 
DA release, but no significant within-group effects of alcohol.  The inconsistent results 
from these studies suggest that the different modalities of alcohol presentation (oral vs. 
IV) might account for the different reports of DA release.  Importantly, conditioned cues 
associated with drug intake might be important in modulating the DA response (this topic 
will be discussed in detail later).   
Regardless of alcohol administration method, several of these studies also 
reported correlations between the magnitude of DA release and the subjective effects of 
alcohol.  Urban et al. (2010) reported a significant positive correlation between change in 
activation on the biphasic alcohol effects scale (BAES) and VST ∆BPND across all 
subjects.  None of the other oral alcohol studies reported such correlations, though one 
did state that self-reported impulsiveness was a significant predictor of VST ∆BPND (the 
direction of this association was unclear, Boileau, 2003).  Two studies by Yoder et al. 
reported positive correlations between subjective intoxication and change in DA after IV 
alcohol.  In one, the magnitude of DA release (number of voxels with ∆BPND > 0) was 
positively related to intoxication (Yoder, 2007), and in the other ∆BPND in the left anterior 
putamen was associated with peak intoxication score (Yoder, 2005).  However, in the 
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latter study, the authors cautioned careful interpretation of the relationship, as it also 
included negative ∆BPND values, such that both increases and decreases in DA 
contributed to the correlation with changes in intoxication.  It is interesting to note that 
the only study of IV alcohol that reported significant alcohol-induced changes in DA in 
response to unexpected alcohol did not find any associations with subjective effects of 
alcohol (Yoder, 2009).  This fact lends support to the authors’ suggestion that the 
changes in DA resulted from violations of reward expectation rather than pharmacologic 
effects of alcohol, thus the dissociation between changes in DA and the subjective 
experience of intoxication. 
 Similarly to alcohol, a large number of studies have investigated DA release in 
response to a nicotine or cigarette challenge in chronic smokers.  By and large, these 
studies have indicated that smoking a tobacco cigarette induces striatal DA release.  
The majority of these reported smoking-induced DA release preferentially in the VST 
(Brody, 2010; Brody, 2009; Brody, 2006; Brody, 2004; Le Foll, 2013; Scott, 2007), but 
some studies using a voxel-wise analysis method reported DA release in dorsal aspects 
of the striatum as well (Domino, 2012; Domino, 2013).  Several of these studies 
attempted to separate the pharmacologic effects of nicotine from the chemosensory 
cues associated with cigarette smoking by including a condition where subjects also 
smoked denicotinized cigarettes (usually containing < 0.1mg nicotine, compared to 
~1mg in a regular cigarette).  Though each of these studies reported greater DA release 
during smoking of a regular cigarette compared to a denicotinized cigarette, there were 
inconsistencies in the variables analyzed across studies.  Two of these studies 
compared only DA release (indicated by ∆BPND) between scans during smoking of either 
a regular cigarette or denicotinized cigarette, but reported no significant within-condition 
effects (Brody, 2009; Scott, 2007).  The other two compared only BPND after regular or 
denicotinized cigarette smoking, rather than differences in ∆BPND between conditions 
(Domino, 2012; Domino, 2013).  This method may have failed to account for baseline 
BPND differences between the two conditions.  Additionally, only one of these studies 
analyzed DA release specifically during smoking of a denicotinized cigarette (pre-
denicotinized BPND vs. post-denicotinized BPND), and reported significant increases in 
dorsal striatal DA (Domino, 2013).  As mentioned previously, this may indicate a DAergic 
response specifically to conditioned cues involved with smoking, but in the absence of 
nicotine (to be discussed later in the Introduction).  To further investigate the pure 
pharmacological effects of nicotine on DA transmission, several studies examined DA 
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release in response to intranasal nicotine or nicotine gum.  Two of these reported no 
significant intranasal nicotine-induced striatal DA release in humans (Montgomery, 2007) 
and non-human primates (Tsukada, 2002), but one claimed that nicotine gum induced 
striatal DA release compared to placebo gum (Takahashi, 2008).  In the latter study, it is 
possible that the placebo gum condition induced a negative prediction error effect in 
smokers, as nicotine was expected but not delivered.  In this manner, their findings could 
be a result of decreased DA during the placebo condition rather than increased DA 
during the nicotine condition.              
 Additionally, many of these studies reported associations between smoking-
induced DA release and subjective variables.  Several studies reported associations of 
DA release with changes in subjective craving, such that greater magnitudes of DA 
release were related to greater decreases in craving (Brody, 2006; Brody, 2004; Le Foll, 
2013).  However, only Le Foll et al. (’13) indicated a unidirectional relationship, whereby 
only positive changes in BPND were associated with reduced craving.  The extent of the 
relationship between DA release and craving in the studies from Brody et al. (2006; 
2004) was not stated.  Several other studies described correlations between smoking or 
nicotine-induced ∆BPND and the hedonic/mood-altering effects of smoking.  All these 
reported positive correlations between ∆BPND and change in euphoria (Barrett, 2004) or 
change in mood from “sad” to “happy” (Brody, 2009; Montgomery, 2007).  However, all  
relationships were bidirectional, involving both increases and decreases in DA, which 
complicates interpretation.  In this manner, increased DA is associated with increased 
euphoria or more happiness, but at the same time, decreased DA is also associated with 
decreased euphoria or more sadness.  While this implies that increases and decreases 
in DA act in an exactly opposing manner, direct evidence to corroborate such a binary 
role for changes in DA is lacking.   Further complicating the issue, none of the above 
relationships are purely bidirectional across all subjects.  For example, in the association 
reported by Brody et al. (2009), striatal DA release was related to improved mood in 
some subjects, and reduced DA was related to decreased mood in others.  However, in 
other subjects, DA release was associated with decreased mood, while reduced DA was 
associated with increased mood in others still.  Though it is tempting to speculate on 
causal relationships between DA release and subjective mood, interpretations of 
bidirectional associations, such as those cited above, should be made carefully.   
 Studies of THC-induced DA release in humans have also yielded equivocal 
results.  Two studies that used oral (Stokes, 2009) and IV THC (Barkus, 2011b), 
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reported no significant striatal DA elevations, although subjects in both studies 
experienced symptoms typical of THC intoxication.  In contrast, a study by Bossong et 
al. (2009) found that inhaled THC vapor elicited a small but significant DA release in the 
VST and preDPU.  Again, as the vapor inhalation paradigm more closely mimics natural 
intake of the drug, the DA release reported by this study may have been related to 
conditioned cues of drug intake (to be discussed in a later section).  In addition, a recent 
investigation used a similar inhalation method in three groups of cannabis users:  
subjects with low risk for psychosis (controls), subjects with diagnosed psychosis 
(patients), and subjects with a first-degree relative with diagnosed psychosis (relatives) 
(Kuepper, 2013).  They documented DA release in the dorsal striatum of both patients 
and relatives, but not controls.  Interestingly, the magnitude of DA release was not 
associated with the behavioral response to THC in any group.  No correlations between 
THC-induced DA release and subjective responses to intoxication were detected in any 
of these investigations.   
 Studies of opiate-induced DA release in abusers have produced more 
concordant results.  Two studies in heroin addicts reported neither significant opiate-
induced changes in striatal DA, nor correlations of DA release to subjective ratings of 
high (Daglish, 2008; Watson, 2013).   
 Taken together, results from the above studies have answered a great deal of 
questions about how human DA systems respond to acute drug administration, yet many 
questions remain unanswered.  While there is little doubt about the importance of DA in 
addiction, the specific roles played by DA in mediating drug effects are unclear.  A 
number of studies reported correlations between drug-induced striatal DA release and 
subjective effects of drug, but the issue is complicated by studies that found no such 
relationships.  Heterogeneity among subject populations, including differences in gender, 
genotype,  severity of addiction and use status (currently using or detoxified), and 
varying sample sizes may all mediate these discrepant results.  One commonality 
running through all these studies is that the mode of drug administration seemingly has 
large effects on the study outcome.  Specifically, studies that utilized a mode of 
administration similar to the natural route of intake demonstrate a trend towards greater 
DA release than those studies attempting to investigate a purely pharmacological effect 
of drug.  The next section will explore the DA response to conditioned drug cues. 
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DA Response to Conditioned Drug Cues in Humans 
 There is indirect evidence from several of the above studies that DA may 
mediate the response to drug conditioned cues.  The fact that greater DA release was 
detected in studies using a more natural route of drug administration (e.g. oral 
consumption of alcohol vs. IV administration, inhalation of THC vs. oral consumption of a 
tablet) suggests that conditioned cues that have been repeatedly paired with drug intake 
(e.g. smell, taste) may activate the striatal DA system separately from than the 
pharmacological effects alone.  In line with this, Domino et al. (2013) showed that 
smoking a denicotinized cigarette resulted in dorsal striatal DA release compared to a 
pre-smoking baseline.  Though these cigarettes did contain a small amount of nicotine 
(0.08mg), much larger doses were unable to elicit detectable amounts of DA in other 
studies (Montgomery, 2007; Tsukada, 2002).  Furthermore, several other investigations 
have attempted to provoke striatal DA release using only cues specifically associated 
with certain drugs of abuse.   
Three separate studies in heavy cocaine abusers compared RAC or FAL BPND 
between two scans:  one during presentation of neutral cues, and the other during 
presentation of cocaine cues (Fotros, 2013; Volkow, 2006b; Wong, 2006).  In each of 
these, striatal DA was significantly elevated during cocaine cue presentation, but 
regional release differed slightly.  Fotros et al. (2013) reported DA release throughout 
the whole striatum, but DA release was confined to the dorsal striatum in the other 
studies.  Interestingly, in the studies by Fotros et al. (2013) and Wong et al. (2006), 
subject responses to the cocaine cues were highly variable, such that the investigators 
divided them into subgroups of “high cravers”, who reported increased craving during 
cocaine cues, and “low cravers”, who reported decreased or negligible craving during 
cocaine cues.  After this separation, only “high cravers” exhibited significant DA release 
during cocaine cues relative to neutral cues in both studies.  Furthermore, each study 
reported that cue-induced striatal DA release was positively correlated with craving, such 
that greater DA release was associated with a more positive cue-induced change in 
craving.  However, all subjects were included in these correlations in two studies (Fotros, 
2013; Volkow, 2006b), while only the “high cravers” were included in the other (Wong, 
2006).  Whether or not the correlations would have survived if “high” or “low” cravers 
were analyzed separately was not indicated in the former two studies.  Though a 
relationship between DA release and craving is supported by the general agreement in 
these studies,  the correlations were not consistent across samples, such that the 
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association of increased DA with reduced craving was present in only a subset of 
subjects in each study.   
A similar study conducted in heroin addicts reported significantly greater cue-
induced DA release in the putamen of addicts compared to healthy controls (Zijlstra, 
2008).  They also reported an inverse correlation between cue-induced craving and 
baseline BPND in the putamen, but not with ∆BPND.  It is important to note that they only 
compared relative ∆BPND between groups, and it is unclear whether there was significant 
cue-induced DA release in addicts alone.  Indeed, in the region where the authors 
reported a significant group effect on ∆BPND, ∆BPND was moderately positive (5%) in 
heroin addicts, and was more strongly negative in controls (-10%).  This discrepancy 
could have artificially inflated the group difference in ∆BPND, and a within-group analysis 
may not have yielded significant ∆BPND for either group.  
Finally, a recent study conducted in a spectrum of alcohol drinkers, whose 
drinking habits ranged from social to heavy, demonstrated VST DA release in response 
to beer flavor compared to a Gatorade control flavor (Oberlin, 2013).  This effect of beer 
flavor on DA release was mediated by family history of alcoholism; when the subjects 
were separated based on degree of family history, significant DA release was detected 
only in subjects with a first degree alcoholic relative.  Although the other family history 
groups displayed increased DA, the release was not significant.   
Taken together, these results indicate that the striatal DA system in humans is 
responsive to conditioned cues associated with drugs of abuse.  Interestingly, cue-
induced DA release was confined to more dorsal striatal areas in heavily addicted 
subjects, whereas it was mainly ventral in subjects with a less severe degree of 
addiction.  This difference could be due to differences in modality of cue presentation, 
but it is also possible that processing of drug-related stimuli shifted to more dorsal 
aspects of the striatum after years of abuse (see above section on temporal changes in 
DA signaling).  In support of this, a recent fMRI study showed that alcohol-related visual 
cues activated ventral striatal areas in light drinkers, but only dorsal striatal regions in 
heavy drinkers (Vollstadt-Klein, 2010).  Additionally, results from the above studies 
emphasize the importance of careful study design and analysis when examining  DA 
release in response to drugs of abuse.         
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Addiction and Impulsivity – Specific Contributions of DA 
 Addiction is a disorder marked by loss of control over substance intake and by 
impulsive behavior.  Individuals suffering from addiction display more impulsive behavior 
on a wide array of neuropsychological indices of impulsivity (for a review, see De Wit, 
2009).  Additionally, a large body of research posits the DA system as an important 
modulator of impulsive behavior, as many brain regions implicated in impulsivity are 
under control of DAergic transmission (see Chapter 3 for a discussion of the 
neurophysiology of impulsivity).  PET imaging offers a unique opportunity to compare 
baseline or activated DA state to different types of impulsive phenotypes.  In humans, 
impulsivity is measured a number of different ways, including self-report (e.g. personality 
questionnaires, history of impulsive behavior), or via performance on cognitive tasks 
(e.g. stop-signal task, delay-discounting).  Several imaging studies have examined 
relationships between estimates of D2 receptor availability/DA release with measures of 
impulsivity.  Two RAC studies in healthy controls reported that scores on the non-
planning impulsivity subscale of the Barratt Impulsivity Scale (BIS-11, Patton, 1995) 
were positively correlated with baseline BPND in the preDCA (Kim, 2013) and ventral 
striatum (Reeves, 2012).  Higher BIS-11 scores indicate greater impulsivity, so these 
results suggest that higher D2 receptor availability is related to higher impulsivity. 
Conversely, another study reported a significant negative correlation between baseline 
FAL BPND and total BIS-11 score in methamphetamine addicts in all striatal regions, 
though strongest in the DCA (Lee, 2009).  Correlations between BIS-11 scores and FAL 
BPND in healthy controls were negative, though none reached significance.  A positive 
relationship between amphetamine-induced DA release in the striatum, but not baseline 
striatal BPND, and BIS-11 score has also been documented in healthy controls 
(Buckholtz, 2010).  Baseline FAL binding in the SN/VTA region in this study was 
negatively correlated with total BIS-11 score.  In agreement with the latter finding, 
baseline FAL binding in the SN/VTA in controls was negatively correlated with novelty 
seeking (Zald, 2008), a subscale on the tridimensional personality questionnaire (TPQ; 
Cloninger, 1987).  Similar to the BIS-11, higher scores on the TPQ signify greater 
impulsivity; thus, these results indicate that greater numbers of D2 autoreceptors in the 
SN/VTA may be associated with relatively less impulsiveness [although an opposite 
effect was detected with PHNO in  both pathological gamblers and controls (Boileau, 
2013)].  Other studies have reported positive relationships between novelty seeking and 
baseline striatal D2 availability (Huang, 2010), as well as amphetamine-induced DA 
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release in the VST (Leyton, 2002).  Interestingly, the seemingly opposing relationships 
between baseline D2 availability and impulsive measures in these studies could 
potentially be explained by a U-shaped association between D2 receptor availability and 
some impulsive constructs.  Indeed, some recent empirical evidence does support this 
hypothesis (Clark, 2012; Gjedde, 2010), but further work is needed.  Though many 
studies have used self-reported measures of impulsivity in their comparison with DAergic 
markers, only one study to date has investigated the relationship between functional 
measures of  impulsivity (as measure by the stop-signal task) and estimates of D2 
availability (Ghahremani, 2012).  In the study, FAL BPND in the dorsal striatum was 
negatively correlated with stop signal reaction time (SSRT), indicating that lower D2 
receptors levels, or higher DA concentrations, are associated with higher impulsivity.  
Furthermore, D2 availability in the DCA was also positively correlated with task-induced 
fMRI activation in the DCA and several cortical regions.  The combined results of these 
studies strongly implicate the DA system as a critical modulator of impulsivity, but high 
variability of results complicates the interpretation.            
 
 The above sections provide a critical review of studies employing dopaminergic 
PET to investigate addiction phenotypes.  There is overwhelming evidence supporting 
an integral role for DA in substance abuse disorders.  Baseline DA receptor availability 
has been associated with chronic substance use in general, as well as with impulsive 
personality traits.  Changes in DA receptor availability in response to a pharmacological 
challenge or cue presentation have been instrumental in characterizing the 
pharmacological effects, or lack thereof, of certain substances.  Cue presentation 
investigations have also yielded novel information about DAergic involvement during the 
experience of craving.  Future studies should be crafted with careful consideration of 
matching controls, study design, analysis, and interpretation.      
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Chapter 1:  Baseline striatal D2/D3 receptor availability in chronic cannabis users 
  
 This chapter describes the use of [11C]raclopride PET to characterize differences 
in the striatal DA system between currently-using chronic cannabis users and healthy 
controls.  In addition, baseline D2/D3 receptor availability in cannabis users was 
investigated for correlations with recent use of cannabis, cannabis craving, and 
personality indices.  Eighteen right-handed males age 18-34 were studied.  Ten subjects 
were chronic cannabis users; eight were demographically matched controls. Subjects 
underwent a [11C]raclopride (RAC) PET scan.  Striatal RAC binding potential (BPND) was 
calculated on both region of interest (ROI) and voxel-wise bases.  Prior to scanning, 
urine samples were obtained from cannabis users for quantification of urine ∆-9-
tetrahydrocannabinol (THC) and THC metabolites (11-nor-∆-9-THC-9-carboxylic acid; 
THC-COOH and 11-hydroxy-THC;OH-THC).   
 Results from this analysis support previous studies that found no differences in 
D2/D3 receptor availability between cannabis users and controls.  Voxel-wise analyses 
revealed that RAC BPND values were negatively associated with both urine levels of 
cannabis metabolites and self-report of recent cannabis consumption.  In this sample, 
current cannabis use was not associated with deficits in striatal D2/D3 receptor 
availability.  There was an inverse relationship between chronic cannabis use and 
striatal RAC BPND.  This article, which was published in Drug and Alcohol Dependence in 
2012, supports the need for additional studies to identify the neurochemical 
consequences of chronic cannabis use on the dopamine system. 
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Introduction 
 
Marijuana (Cannabis sativa) is one of the most commonly abused illicit drugs in 
the United States.  Over 106 million people age 12 and above (42%) have reported 
using cannabis at least once.  Although the addictive liability of cannabis is a source of 
debate, cannabis dependence remains a serious health concern (Clapper, 2009):  over 
1,000,000 Americans received treatment for cannabis abuse or dependence within the 
past year (Samhsa, 2010).  The large number of Americans at risk for cannabis abuse 
and dependence necessitates a better understanding of the neurobiology of cannabis 
use disorders.   
The main psychoactive component of cannabis, ∆9-tetrahydrocannabinol (THC), 
exerts its effects via binding the cannabinoid type 1 (CB1) receptor (Devane, 1988; 
Herkenham, 1991; Herkenham, 1990; Mailleux, 1992).  CB1 receptors are expressed 
throughout the brain, with high densities in the cortex, hippocampus, cerebellum, and 
striatum.  This heterogeneous distribution of CB1 has been confirmed in both humans 
and non-human primates (Eggan, 2007). The role of the striatum in cannabis use is of 
particular interest, as this structure is often involved in multiple cognitive processes that 
subserve addiction.  The striatum is heavily innervated by midbrain dopamine (DA) 
neurons, and striatal dopaminergic neurotransmission is believed to mediate both the 
development and maintenance of addictions (for review see Robinson, 2001; Robinson, 
2003).   
There is a growing body of in vivo evidence that suggests striatal DA receptors 
may be altered in human addicts.  PET and SPECT imaging studies have documented 
deficits in striatal D2/D3 receptor availability in several populations of abstinent and/or 
detoxified substance-dependent individuals, including users of cocaine (Martinez, 2009; 
Volkow, 1997), methamphetamine (Volkow, 2001b), opiates (Wang, 1997b), and alcohol 
[(Hietala, 1994; Martinez, 2005; Volkow, 1996; Volkow, 2002), although see (Guardia, 
2000a; Repo, 1999a)].  Interestingly, this phenomenon has not been demonstrated in 
cannabis users.  Three studies investigating striatal D2/D3 receptor availability in subjects 
with a history of cannabis use found negligible differences between cannabis users and 
controls (Sevy, 2008a; Stokes, 2011; Urban, 2012a).  However, these studies were 
conducted in subjects that had been abstinent from cannabis for an average of 15 weeks 
(Sevy, 2008a), 18 months (Stokes, 2011), and 4 weeks (Urban, 2012a).  There is 
evidence to suggest that reduced D2/D3 receptor availability in addicts may recover after 
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extended periods of abstinence (Volkow, 2002), although the rate of recovery is highly 
variable between individuals (Nader, 2006).   
 In order to better understand the role of DA in cannabis dependence, it is crucial 
to study individuals who are current heavy cannabis users.  To date, no one has 
examined striatal D2/D3 binding in currently-using chronic cannabis users.  Here, we 
used PET and [11C]raclopride (RAC), a D2/D3 antagonist, to compare striatal D2/D3 
availability in currently-using chronic cannabis users and age-matched healthy controls.  
We hypothesized that RAC binding availability would be lower in chronic cannabis 
smokers relative to controls.   
 
Methods 
 
 All study procedures were approved by the Indiana University Institutional 
Review Board.  Subjects were recruited by local advertising in the greater metropolitan 
Indianapolis area.  All subjects signed an informed consent statement.  Eighteen right-
handed males completed the study.  Participants in the cannabis group (CAN; n = 10) 
were chronic cannabis users, defined by consumption of at least one “joint” per week (or 
equivalent) in the last month and a positive result for THC on a urine toxicology screen 
(Skosnik, 2008a; Skosnik, 2006; Skosnik, 2008b).  Control subjects (CON; n = 8) were 
non-cannabis smoking males with negative urine toxicology screens.  Groups were 
matched for age and race.  Subjects underwent a screening interview that included:  the 
Structured Clinical Diagnostic Interview for DSM-IV disorders (SCID) I and II, and the 
Edinburgh handedness inventory (Oldfield, 1971).  Patterns of alcohol and substance 
use were ascertained using the SCID I module E for Substance Use Disorders.  
Exclusion criteria were:  history of any neurological disorder, current use of medications 
with CNS effects, consumption of > 14 alcoholic beverages per week, contraindication 
for magnetic resonance imaging (MRI), use of any illicit substance during the past three 
months (except cannabis in CAN subjects), positive urine toxicology screen (other than 
cannabis in CAN subjects), and DSM-IV diagnosis of an Axis I or II psychiatric disorder 
(other than nicotine abuse or dependence in any subject, and cannabis abuse or 
dependence in CAN subjects).  History of illicit substance abuse or dependence (other 
than cannabis in CAN) was exclusionary for all subjects.  
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General Study Procedures 
 On a day subsequent to the screening visit, qualified subjects received a 
structural magnetic resonance image (MRI) and one [11C]raclopride PET scan.  Before 
scanning, subjects reported recent substance use-patterns using an internally developed 
drug-use questionnaire.  All subjects submitted a urine sample for drug toxicology 
screening.  Urine toxicology screens (Q10-1, Proxam) were administered prior to 
scanning to corroborate self-report and clinical interview.  For quantitative cannabinoid 
analysis, urine samples from CAN subjects were submitted to The Center for Human 
Toxicology at the University of Utah for quantification of ∆9-tetrahydrocannabinol (THC), 
11-nor-∆9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH), 11-hydroxy-∆9-
tetrahydrocannabinol (OH-THC), and creatinine.  CAN subjects were instructed to refrain 
from smoking cannabis the morning before the scan to help ensure they would not be 
intoxicated at the time of scanning.   
 
Image Acquisition  
 A magnetized prepared rapid gradient echo (MP-RAGE) MRI was acquired on all 
subjects using a Siemens 3T Trio for anatomic co-registration of PET data.  RAC was 
synthesized as reported previously (Fei, 2004a).  RAC PET scans were acquired on an 
ECAT HR+ (3D mode; septa retracted).  Prior to each PET scan, a 10-min transmission 
scan using three internal rod sources was acquired for attenuation correction. RAC PET 
scans were initiated with an IV infusion of 544.39 ± 38.7 MBq RAC over the course of 
1.5 minutes.  Injected mass was 0.17 ± 0.08 nmol/kg.  Dynamic data acquisition lasted 
50 minutes.  
During scanning, CAN subjects responded to statements designed to assess 
cannabis craving.  These included:  “I want to smoke cannabis right now”; “I have an 
urge to smoke cannabis right now”; “It would be great to use cannabis right now”; 
“Nothing would be better than smoking cannabis right now.”  Responses were given on a 
Likert-like scale, anchored by 1 (strongly disagree) and 7 (strongly agree).  The area 
under the curve (AUC) for responses to each of the cannabis craving statements was 
calculated using the trapezoidal rule.  The average AUC value across all 4 statements 
was used as an overall craving metric.   
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Image Processing  
 Image processing is similar to that described previously (Yoder, 2011a; Yoder, 
2012a).  MRI DICOM and RAC PET images were converted to Neuroimaging 
Informatics Technology Initiative (NIfTI) format (http://nifti.nimh.nih.gov/) and processed 
with SPM5 (http://www.fil.ion.ucl.ac.uk/spm/).  For each subject, an early-time mean PET 
image was co-registered to the MRI scan using the normalized mutual information 
algorithm in SPM5.  All dynamic PET data were co-registered to the early-time mean 
PET image (in native MR space) to facilitate motion correction.  Each subject’s MRI was 
spatially normalized to Montreal Neurological Institute (MNI) space, and this 
transformation matrix was then applied to the motion-corrected, MRI-registered PET 
data from each subject.   
 
Region of Interest Analysis  
 Regions of interest (ROIs) were drawn on each subjects’ normalized MRI using 
MRIcron (http://www.cabiatl.com/mricro/mricron/).  Striatal ROIs consisted of the left and 
right ventral striatum (VST), pre- and postcommissural dorsal caudate (pre-/post-DCA), 
and pre- and postcommissural dorsal putamen (pre/post-DPU) and were drawn 
according to specific anatomic landmarks (Martinez, 2003).  For the reference region 
(tissue that contains little to no D2/D3 receptor density), an ROI was created that 
contained all cerebellar gray matter except for the vermis.  Cerebellar ROIs were created 
for each subject by tracing the cerebellum on individual gray matter maps obtained with 
the segmentation algorithm in SPM5.  Time-activity curves for all ROIs were generated 
from the dynamic RAC data using the MarsBaR toolbox for SPM5 
(http://marsbar.sourceforge.net/).  For each striatal ROI, D2/D3 receptor availability was 
indexed with BPND, the binding potential of RAC calculated as bound tracer 
concentration relative to nondisplaceable tracer concentration (Innis, 2007).  Estimations 
of BPND were conducted using the multilinear reference tissue method model (MRTM2; 
Ichise, 2003).   
 
Voxel-wise Analysis 
 BPND was estimated at each brain voxel using the multilinear reference tissue 
method with a common reference region efflux rate to facilitate robust performance on 
noisy voxel data (MRTM2; Ichise, 2003).  The resulting parametric BPND images were 
smoothed with an 8mm Gaussian kernel (Costes, 2005; Picard, 2006; Ziolko, 2006).  
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The search area for the voxel-wise paired t-tests was restricted to the striatum, as (1) 
our sole focus was the striatum, and (2) the striatum has the highest density of D2/D3 
receptors in the brain, and is the only brain structure with high enough signal-to-noise 
ratio to support quantification of D2/D3 receptor availability with RAC.  A bilateral striatal 
restriction mask was created by tracing the anatomical boundaries of the striatum on an 
averaged normalized MRI across all subjects.     
 
Urinalysis 
THC and THC-COOH:  The samples were initially analyzed for THC and THC-
COOH by gas chromatography-mass spectrometry (GC-MS) using extraction and GC-
MS conditions described previously (Foltz, 1983; Huang, 2001).  The assay had an 
analytical range of 0.5 to 100 ng/mL with 1.0 mL aliquots.  To ensure measurement of 
both analytes, the urine samples were analyzed for THC on a 1-0-mL aliquot and THC-
COOH on a 0.1-mL aliquot.  For THC, the aliquots were pretreated with ß-glucuronidase 
for 18 hours at 37˚C.  For THC-COOH, the samples were prepared under basic 
conditions in order to free THC-COOH from its glucuronide conjugate.   Duplicate 
calibrators (1.0 mL with both THC-COOH and THC) were at 0.5, 1.0, 2.5, 5, 10, 25, 50 
and 100 ng/mL. Duplicate 1.0-mL (with both THC-COOH and THC) quality control 
samples (QCs) were included at 1.5, 10 and 80 ng/mL.  Triplicate 0.1 mL dilution QCs 
were included at 200 ng/mL.  Samples were extracted by a liquid-liquid procedure, 
derivatized with hexafluoroisopropanol/trifluoroacetic anhydride, and analyzed by GC-
MS. 
Subsequently, the method was improved by using gas chromatography-tandem 
mass spectrometry (GC-MS/MS) with addition of 11-hydroxy-∆9-tetrahydrocannabinol 
(OH-THC) to the assay.  This assay had a quantitative range of 0.1 to 100 ng/mL with a 
1.0-mL aliquot.  All samples were reanalyzed to determine OH-THC with the ß-
glucuronidase pretreatment using the above methods.  Samples with THC or THC-
COOH results less than the lower limit of quantitation in the initial analysis were 
reanalyzed. 
Creatinine – Creatinine was determined using a microplate colormetric test 
based on the Jaffe reaction where picric acid reacts with creatinine to form a colored 
product.  Samples were diluted 10-fold (0.050 mL plus 0.450 mL water).  Duplicate 
creatinine calibrators were run at 2, 4, 6, 8, 10, 12 and 15 mg/dL.  Due to sample 
dilution, the calibration range was 20 to 150 mg/dL.  Triplicate diluted low and high QCs 
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were included.  Samples outside the calibration range were repeated using a smaller or 
larger dilution as needed.  THC, THC-COOH, and OH-THC concentrations were 
normalized by creatinine levels to account for differing levels of urine dilution across 
subjects (THC/Cr, THC-COOH/Cr, and OH-THC/Cr respectively). 
 
Statistical Analysis  
 Independent t-tests were used to test for differences between CAN and CON in 
demographic variables, substance abuse metrics, PAS, and SPQ scores, and RAC 
BPND.  Group differences in BPND were assessed with ROI and voxel-wise analyses.   
Pearson’s correlation coefficient was used to screen variables for associations with 
striatal ROI BPND.  Multiple linear regression models in SPM5 were used to test for 
correlations on a voxel-wise basis. SPM5 was used for voxel-wise analysis, statistical 
threshold was set at p < 0.05.  All other statistical procedures were performed in SPSS 
19.0 (SPSS, Chicago, Illinois, USA). 
 
Results 
 
Subject Data  
 The demographic and substance abuse characteristics of subjects are shown in 
Table 1.   CAN and CON subjects were not significantly different in any of the indices.  
Groups were well-matched for race, ethnicity, and use of alcohol, tobacco, and caffeine.  
There were no significant differences between injected radioactivity or injected mass 
between groups (p > 0.1).   
 
Urine THC and THC Metabolite Corroborate Self-Report of Cannabis Consumption 
 THC/Cr, THC-COOH/Cr, and OH-THC/Cr levels were correlated with self-
reported recent cannabis use.  One subject was excluded from this analysis because of 
inconsistent self-report data.  Significant positive correlations existed between:  intake 
per day and THC-COOH/Cr (r = 0.884, p = 0.002), intake per day and THC/Cr (r = 0.738, 
p = 0.023), intake per week and THC-COOH/Cr (r = 0.726, p = 0.027), and intake per 
month and THC-COOH/Cr (r = 0.676, p = 0.045).  There was a trend-level association 
between intake per day and OH-THC/Cr (r = 0.647, p = 0.059).  There were no 
significant correlations between THC/Cr, THC-COOH/Cr, or OH-THC/Cr and cannabis 
craving during PET scanning.   
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Table 1.  Subject demographics and drug-use characteristics.  THC use is defined as a 
one-time session of THC intoxication.  Data are mean ± s.d.  Healthy controls:  CON; 
currently using chronic cannabis users:  CAN; Caucasian:  C; African American:  AA; 
Asian-Indian American:  I; Non-Hispanic Latino:  NHL; not applicable:  N/A.   Recent 
EtOH use is average drinks per week in the past month.  
 CON  (n = 8) CAN (n = 10) p 
Age 26.4 ± 5.6 25.1 ± 4.6 n.s. 
Race 7C, 1AA 6C, 3AA, 1I n.s. 
Ethnicity 8 NHL 10 NHL n.s. 
Education 14.6 ± 1.3 14.0 ± 1.8 n.s. 
Recent THC use/wk N/A 12.7 ± 12  
Recent THC use/month N/A 46.6 ± 42  
Years of THC use N/A 8.8 ± 5  
Hours since last THC use N/A 20.6 ± 8.3  
Tobacco users 2 5 n.s. 
Caffeine users 5 6 n.s. 
Recent EtOH use 2.94 ± 2.0 3.93 ± 3.7 n.s. 
Premorbid IQ 112.3 ± 6.9 110.2 ± 4.4 n.s. 
 Prior Drug Use: 
(lifetime drug use 
sessions) 
   
THC 36.1 ± 71.7 2571.4 ± 2490.5 
0.0
1 
Sedatives 0 0.65 ± 1.7 n.s. 
MDMA 0 1.20 ± 3.1 n.s. 
Stimulants 0 0.20 ± 0.4 n.s. 
Cocaine 0.63 ± 1.8 4.20 ± 6.3 n.s. 
Opiates 0 0.10 ± 0.3 n.s. 
Hallucinogens 1.31 ± 2.7 1.20 ± 1.6 n.s. 
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Striatal D2/D3 Availability  
CAN vs. CON 
There were no significant between group differences in RAC BPND detected by voxel-
wise analysis.  Similarly, no group differences were found for any of the 10 striatal ROIs 
assessed (p > 0.4) (Table 2). 
Correlation with Recent Cannabis Consumption 
Voxel-wise analysis revealed that RAC BPND was negatively associated with both 
urine levels of THC-COOH (Figure 1) and self-reported recent intake per day (Figure 2).  
Similar correlations were found between BPND and THC/Cr, OH-THC/Cr, recent intake 
per week, and recent intake per month (data not shown).      
 
Discussion 
  
 The present work is the first to demonstrate an association between the 
magnitude of recent cannabis consumption and striatal D2/D3 receptor availability.  RAC 
BPND was strongly negatively correlated with both urine THC-COOH and self-reported 
recent intake per day.  We did not find the expected differences in striatal D2/D3 receptor 
availability between cannabis users and controls, similar to what has been reported 
previously (Sevy, 2008a; Stokes, 2011; Urban, 2012a).   
 The inverse correlation between recent cannabis consumption (as confirmed by 
urine THC metabolite levels) and D2/D3 receptor availability could be interpreted as a 
direct effect of cannabis smoking via lower expression of striatal DA receptors, or 
increased basal DA concentration.  There is evidence that suggests that heavy cannabis 
use results in inhibition of MAO activity (Schurr, 1984; Stillman, 1978), and thus a higher 
striatal DA tone (Kaseda, 1999; Lakshmana, 1998; Lamensdorf, 1996).  Alternatively, 
activation of CB1 receptors may also result in higher striatal DA concentration (Chen, 
1990; Fadda, 2006b; Tanda, 1997b).  We must consider the possibility that, in this study, 
residual THC from the most recent smoking session increased striatal DA levels; 
however, several lines of evidence suggest otherwise.  Human imaging studies have 
attempted to demonstrate THC-induced DA release, with inconclusive results.  One 
study reported a small (3%) increase in striatal DA after inhaled THC (Bossong, 2009), 
while two other groups detected no increases in striatal DA after either oral (Stokes, 
2009) or IV-delivered THC (Barkus, 2011a).  Additionally, in the present work, it is  
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Table 2.  Region of interest analysis:  comparison of striatal binding potential between 
chronic cannabis users (CAN) and healthy controls (CON).  Groups are matched for 
cigarette smoking status.  Left/right:  L/R; pre/post-commissural:  pre/post; dorsal 
caudate:  DCA; dorsal putamen:  DPU; ventral striatum:  VST.         
 
[11C]RACLOPRIDE RECEPTOR AVAILABILITY 
(BPND)  
Region  CON (n = 8) CAN (n = 10) p 
L pre-DCA 2.37 ± 0.29 2.30 ± 0.32 0.63 
R pre-DCA  2.34 ± 0.30 2.23 ± 0.29 0.44 
L post-DCA 1.51 ± 0.27 1.59 ± 0.28 0.56 
R post-DCA  1.55 ± 0.33 1.64 ± 0.19 0.52 
L pre-DPU 3.08 ± 0.32 2.92 ± 0.29 0.28 
R pre-DPU  3.04 ± 0.30 2.94 ± 0.22 0.44 
L post-DPU 3.11 ± 0.31 2.98 ± 0.32 0.40 
R post-DPU  3.00 ± 0.33 2.92 ± 0.32 0.63 
L VST 2.52 ± 0.29 2.47 ± 0.33 0.78 
R VST  2.29 ± 0.25 2.35 ± 0.23 0.58 
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Figure 1.  A.  Voxel-wise correlations between urine THC-COOH/Cr with RAC BPND in 
cannabis users (n = 10).  The “rainbow” colorscale indicates voxels where BPND is 
correlated with THC-COOH/Cr.  B.  Linear relationship between BPND and urine THC-
COOH levels.  Average BPND value was determined for each subject by extracting BPND 
values with a region of interest defined by the significant voxels from the SPM result 
(shown in 1A).  Display threshold is p < 0.01.  MNI coordinates are:  axial:  6; coronal:  
24.       
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Figure 2.  A.  Voxel-wise correlations between self-reported average intake per day and 
RAC BPND in cannabis users (n = 9).  The “rainbow” colorscale indicates voxels where 
BPND is correlated with average use per day.  B.  Linear relationship between BPND 
values and recent cannabis use per day.  Average BPND value was determined for each 
subject by extracting BPND values with a region of interest defined by the significant 
voxels from the SPM result (shown in 2A).  Display threshold is p < 0.01.  MNI 
coordinates are:  axial:  6; coronal:  24.       
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unlikely that brain levels of THC or psychoactive metabolite were sufficient to induce 
measurable DA release.  In a recently described pig model that closely mimics the 
kinetic profile of THC in humans, the concentration of a dose of IV-administered THC 
was greatly reduced in the brain after six hours, and completely absent after 24 hours 
(Brunet, 2006).  Given that subjects in the present study had abstained from smoking an 
average of 20.6 hours prior to scanning, it is likely that brain levels of THC were 
negligible.          
 It is also possible that the relationship between cannabis consumption and 
striatal D2/D3 receptor availability is a result of lower D2/D3 receptor numbers in heavy 
cannabis users.  Interestingly, evidence from studies of CB1 receptors supports this 
interpretation.  CB1 receptors are co-localized with D2 receptors in the striatum 
(Hermann, 2002; Mailleux, 1992; Pickel, 2006; Wenger, 2003) and D2 receptors and 
CB1 receptors form heterodimeric receptor complexes (Kearn, 2005).  A postmortem 
study showed that long-term cannabis users possess a marked reduction in the density 
of CB1 in human brain (Villares, 2007).  Additionally, it has been demonstrated that 
chronic cannabis users exhibit motor learning deficits similar to those observed in CB1 
knockout mice, suggesting that long-term cannabis exposure induces robust 
downregulation and/or desensitization of CB1 receptors (Skosnik, 2008a).  This has 
recently been shown in vivo in humans using the CB1 tracer [18F]FMPEP-d2.  Hirvonen 
et al. (2011) demonstrated CB1 downregulation in chronic cannabis users, which 
correlated with total years of cannabis exposure. CB1 availability returned to normal 
levels after four weeks of monitored abstinence.  Taken together, the data from the 
literature indirectly suggest that chronic exposure to cannabis may lead to 
downregulation of striatal D2 receptors.  However, in the present study, we did not find 
differences in D2/D3 receptor availability between controls and chronic cannabis users, 
suggesting that chronic cannabis exposure alone is not associated with reduced D2 
receptor levels.    
 Finally, there is one additional putative explanation for the association of recent 
cannabis consumption and D2/D3 receptor availability.  It is possible that individuals with 
relatively lower D2/D3 receptor availability are predisposed to engage in higher levels of 
substance use.  It has been suggested that lower baseline striatal DA receptor 
availability is associated with a more positive subjective response to a reinforcing 
DAergic stimulus (Volkow, 1999), indicating that lower DA receptor availability could 
confer an increased likelihood to abuse substances.  In agreement with this, others have 
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argued that lower levels of D2 receptors increase the probability of addictive behavior 
(Blum, 2000; Blum, 1996), and that higher levels of D2 receptors might serve as a 
protective mechanism that reduces the likelihood of substance abuse (Volkow, 2006a).  
In the current dataset, cannabis users with the highest recent cannabis consumption 
exhibited the lowest D2/D3 receptor availability.  According to the above studies, the 
predilection to engage in heavier use of cannabis could be a result of relatively lower 
premorbid levels of D2 receptors in these subjects.  However, if the probability of 
engaging in substance abuse was indeed associated with lower levels of D2 receptor 
expression in the current sample, one would expect to detect significant group 
differences in D2/D3 receptor availability between cannabis users and controls, which 
was not the case.  This issue is further complicated due to: 1) the cross-sectional nature 
of the study, as there is no way to resolve differences in DA function that occur prior to 
substance use from those that are a result of prolonged substance use, and 2) the 
nature of PET methodology is such that relative contributions of receptor expression 
levels versus concentration of endogenous DA to BPND cannot be parsed.  Longitudinal 
studies that employ other techniques, such as DA challenges, will be useful in 
elucidating this issue.          
 The present study has several limitations.  The sample size is relatively small, 
and thus presents a risk of both Type I and Type II errors.  However, our data are 
consistent with those from Sevy et al. (2008a), Stokes et al. (2011), and Urban et al. 
(2012a), which reported that striatal D2/D3 receptor availability is not different in 
individuals with a history of cannabis abuse compared to controls.  Finally, although use 
of any illicit substance within the last three months prior to scanning was an exclusion 
criterion, both cannabis users and controls had previous experiences with other drugs.  
Thus, we cannot preclude the possibility that prior use of other illicit substances 
confounded our data.  However, qualitative examination of the data did not indicate that 
subjects with previous drug experience were outliers with respect to BPND. 
 In conclusion, the primary finding of the current study is that current cannabis use 
is not associated with a reduction in striatal DA receptor availability relative to controls.  
We also found that recent cannabis use is negatively correlated with striatal D2/D3 
availability.  Future studies are needed to better understand the neurochemical basis of 
this finding.   
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Chapter 2:  Effects of cigarette smoking on striatal D2/D3 receptor availability in 
alcoholics and social drinkers 
 
 This chapter describes the use of [11C]raclopride PET to assess the degree to 
which comorbid alcohol and tobacco abuse is associated with deficits in the striatal DA 
system.  Eighty-one subjects (34 nontreatment-seeking alcoholic smokers [NTS-S], 21 
social-drinking smokers [SD-S], and 26 social-drinking non-smokers [SD-NS]) received 
baseline [11C]raclopride scans.  All but seven of the smoking subjects received a 
transdermal nicotine patch during the scan day.  D2/D3 binding potential (BPND ≡ Bavail/KD) 
was estimated for ten anatomically defined striatal regions of interest (ROIs).  ANOVA 
was used to detect BPND differences between the three groups.  Pearson’s correlation 
coefficient was used to assess associations between striatal BPND and subjective 
variables.     
 Results from an ANOVA demonstrated significant group effects in bilateral pre-
commissural dorsal putamen, bilateral pre-commissural dorsal caudate, and bilateral 
post-commissural dorsal putamen.  Post-hoc testing revealed that, regardless of drinking 
status, smokers had lower striatal D2/D3 receptor availability than non-smoking controls.   
This effect appears to be independent of nicotine patch administration.  We hypothesize 
that the observed effect is related to inhibition of brain monoamine oxidase (MAO) by 
tobacco combustion products, and subsequently higher intrasynaptic DA concentration.  
Additional studies are needed to identify the mechanisms by which chronic tobacco 
smoking is associated with striatal dopamine receptor availability. 
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Introduction 
 
Alcohol and tobacco are the two most commonly abused substances in the 
United States.  In people over the age of 12, the percentage reporting lifetime use of 
alcohol is 82.5%, and 67.5% for tobacco (Samhsa, 2011).  These two drugs interact in 
several domains.  Specifically, tobacco cigarette-dependent individuals are 
approximately six times more likely to be alcohol dependent than non-tobacco cigarette-
dependent individuals (Grant, 2004), and alcohol-dependent individuals are over five 
times more likely to be tobacco cigarette-dependent than non-alcohol-dependent 
individuals (Hasin, 2007).  Comorbid abuse of alcohol and cigarettes has also been 
associated with higher rates of certain types of cancer than the abuse of either 
substance in isolation, including oral, laryngeal, esophageal, and liver cancer (Pelucchi, 
2006).  Evidence for additive effects of alcohol and cigarettes on cardiovascular disease 
is less conclusive (Mukamal, 2006).  Even so, abuse of either substance imparts 
increased risk for cardiovascular disease.  Overall, the economic burden of alcohol and 
cigarette abuse in the U.S. is estimated at $185 billion (Harwood, 2000) and $138 billion 
(Rice, 1999), respectively.  
 Many factors likely contribute to the prevalence of comorbid alcohol and cigarette 
abuse (Drobes, 2002), including the potential overlap of neurobiological mechanisms 
that subserve alcohol and cigarette dependence.  One circuit implicated in most, if not 
all, addictive processes is the striatal dopamine (DA) system (Di Chiara, 1988a; Koob, 
1992; Leshner, 1999; Robinson, 2003; Volkow, 2009).  A growing body of in vivo 
evidence suggests that striatal DA receptors may be altered in human addicts.  PET and 
SPECT imaging studies have documented lower striatal D2/D3 receptor availability in 
several populations of abstinent and/or detoxified substance-dependent individuals, 
including users of cocaine (Martinez, 2009; Volkow, 1997), methamphetamine (Volkow, 
2001b), opiates (Wang, 1997b), alcohol [(Heinz, 2004; Hietala, 1994; Martinez, 2005; 
Volkow, 1996; Volkow, 2002), although see (Guardia, 2000a; Repo, 1999a)], and 
cigarette-smoking subjects [(Busto, 2009; Fehr, 2008), although see (Yang, 2006)].  
The high occurrence of comorbid alcohol and cigarette abuse, coupled with the 
association of both substances with deficits in the striatal dopaminergic (DAergic) 
system, are suggestive that alcohol and cigarettes act similarly on neurobiological 
circuits that underlie addiction.  However, it is currently unknown if the individuals who 
abuse both alcohol and cigarettes have similar or greater deficits in D2/D3 availability 
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compared to those who abuse only one substance.   To begin to address this question, 
we conducted a retrospective analysis of baseline [11C]raclopride (RAC) PET data 
collected from several studies in the laboratory (RAC is a dopamine D2/D3 receptor 
antagonist used to estimate in vivo striatal receptor density).  Baseline RAC PET data 
were compiled for three groups:  nontreatment-seeking alcoholic smokers (NTS-S), 
social-drinking smokers (SD-S), and social-drinking non-smokers (SD-NS).  We 
hypothesized that chronic, comorbid alcohol and cigarette abuse would be associated 
with greater deficits in D2/D3 receptor availability than abuse of cigarettes alone. 
 
Methods 
  
 All study procedures were approved by the Indiana University Institutional 
Review Board and performed in accordance with the ethical standards of the Belmont 
Report.  Subjects were recruited by local advertising in the greater Indianapolis area.  
After a complete description of the study to the subjects, written informed consent was 
obtained.  Eighty-one right-hand dominant, adult subjects completed study procedures.  
Data from subsets of subjects have been published previously (Albrecht, 2012b; Yoder, 
2011b; Yoder, 2012b).  The presence or absence of alcohol abuse or dependence was 
assessed by either by the Semi-Structured Assessment for the Genetics of Alcoholism 
(Bucholz, 1994) (n = 73) or the Structured Clinical Diagnostic Interview for DSM-IV 
disorders (SCID) I Substance Use Disorders section (Module E) (n = 8).  For all subjects, 
the absence of illicit substance abuse or dependence was confirmed by the SCID-I 
Substance Use Disorders section.  Subjects were excluded from participation if they 
endorsed recreational use of legal or illicit stimulants, pain medications, sedatives, 
and/or regular consumption of >2 marijuana cigarettes (or equivalent) per week.  Urine 
toxicology screens (Q-10, Proxam) were administered during the screening visit, and on 
the day of PET imaging.  Any positive result for an illicit substance on the screening visit 
was exclusionary (with the exception of THC when sporadic use was endorsed).  
Positive results on the day of scanning were recorded.  NTS-S subjects had not received 
treatment for alcohol use disorders within the past year and were not actively seeking 
treatment.  In cigarette smokers, tobacco dependence was assessed with the 
Fagerström Test for Nicotine Dependence (Pomerleau, 1994); these data were 
unavailable for three smoking subjects.   
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General Scan Day Procedures 
Subject sobriety was confirmed by BrAC measurement prior to scan day 
procedures for the majority of subjects (n = 73); BrAC was not measured in eight control 
subjects.  Subjects received a structural MRI and a baseline [11C]raclopride (RAC) PET 
scan.  All but seven smoking subjects received a transdermal nicotine patch, which has 
been shown to effectively control craving; variance in baseline RAC binding is also 
stable with patch placement (Yoder, 2011b; Yoder, 2012b).  Patch placement occurred 
approximately 5.5 hours before RAC PET scanning (mean, 5.42 hours; range, 1-7 
hours). Patch dose was based on subjects’ self-report of number of cigarettes smoked 
per day, per package instructions.  Thirty-seven subjects received a 21mg patch, 10 
received a 14mg patch, and one subject received a 7mg patch.  Cigarette craving was 
measured with the second dimension of the Cigarette Withdrawal Scale (CWS; (Etter, 
2005)), which specifically captures the individual’s current subjective state of cigarette 
craving.  There are four items in this dimension, anchored by 1 (totally disagree) and 5 
(totally agree).  The final metric is a composite sum of the scores for each item; thus, the 
craving score range is 4-20.  Cigarette craving data were available for 47 of the 55 
smoking subjects.  Forty-two of these subjects completed a paper version of the CWS 
prior to the rest scan; 5 subjects completed an electronic version immediately after RAC 
injection.  On the day of scanning, two NTS subjects tested positive for cocaine, though 
both subjects denied recent cocaine use.  One NTS and one SD-S subject tested 
positive for opiates on the scan day; both subjects reported that drugs had been 
prescribed for recent dental work.  As previously described (Yoder, 2011b), NTS 
subjects were monitored for alcohol withdrawal  with the Clinical Withdrawal Assessment 
for Alcohol, Revised (CIWA-Ar; (Sullivan, 1989)).   
 
Image Acquisition 
A magnetized prepared rapid gradient echo (MP-RAGE) magnetic resonance 
image (MRI) was acquired using a Siemens 3T Trio for anatomic co-registration of PET 
data.  RAC was synthesized as reported previously (Fei, 2004b).  RAC PET scans were 
acquired on an ECAT HR+ (3D mode; septa retracted).  Prior to each PET scan, a 10-
min transmission scan using three internal rod sources was acquired for attenuation 
correction. RAC PET scans were initiated with an IV infusion of 522.4 ± 55.6 MBq RAC 
over the course of 1.5 minutes.  Injected mass was 0.14 ± 0.07 nmol/kg.  Dynamic data 
acquisition lasted 50 minutes.   
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Image Processing 
 Image processing was similar to that described previously (Yoder, 2011b; Yoder, 
2012b).  MRI and PET images were converted to Neuroimaging Informatics Technology 
Initiative (NIfTI) format (http://nifti.nimh.nih.gov/) and processed with SPM5 
(http://www.fil.ion.ucl.ac.uk/spm/).  For each subject, an early mean PET image was 
coregistered to the anatomic MRI using the mutual information (MI) algorithm in SPM5.  
Each subject’s MRI was spatially normalized to Montreal Neurological Institute (MNI) 
space. The transformation matrix obtained from the spatial normalization step was then 
applied to the motion-corrected, MRI-registered PET data from each subject.    
 
Region of Interest Analysis 
 Regions of interest (ROIs) were drawn on individual subjects’ spatially 
normalized MRIs using MRIcron (http://www.cabiatl.com/mricro/mricron/).  Striatal ROIs 
were drawn according to specific anatomic landmarks (Martinez, 2003; Mawlawi, 2001), 
and consisted of the left and right ventral striatum (VST), pre- and postcommissural 
dorsal caudate (pre-/post-DCA), and pre- and postcommissural dorsal putamen 
(pre/post-DPU).  Individual cerebellar ROIs were used as the reference region (tissue 
that contains little to no D2/D3 receptor density).  Individual gray matter cerebellar ROIs 
were created for each subject; the vermis was excluded.  For each subject and each 
ROI, the number of voxels in the ROI was recorded and converted to volume (cc).  Time-
activity curves for all ROIs were extracted from the dynamic RAC data using the 
MarsBaR toolbox (http://marsbar.sourceforge.net/).  The RAC binding potential for each 
ROI ((defined as bound tracer concentration relative to nondisplaceable tracer 
concentration; BPND (Innis, 2007)) was estimated with the multilinear reference tissue 
method model (MRTM; Ichise, 2003).  One subject had a substantial atrophy of the 
caudate; caudate data from this individual were excluded from analyses.           
 
Statistical Analysis 
 One-way analysis of variance (ANOVA) was used to test for mean differences in 
outcome variables across the three groups.  To identify sources of significant group 
effects, post-hoc testing was conducted using the Least Square Difference (LSD) 
method.  Bonferroni corrections were applied to account for multiple comparisons.  To 
test for effects of nicotine patch on BPND, one-way ANOVA was conducted in subsets of 
age-matched smokers, with nicotine patch dose as a fixed factor (no patch; 7/14 mg; 21 
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mg).  Pearson’s correlation coefficient was used to test for associations between striatal 
BPND and subjective variables.  Statistical tests were performed in Microsoft Excel 2007 
or SPSS 19.  Unless otherwise specified (e.g., in the case of Bonferroni correction), 
statistical significance was set at p < 0.05.    
 
Results 
 
Subject Characteristics 
 Subject demographics and drinking characteristics are shown in Table 3.  Groups 
were balanced for handedness, race, ethnicity, and education.  Fagerström scores were 
not significantly different between smoking groups (Table 3).  There was a main effect of 
group for number of drinks per week (p < 1.0 x 10-15).  Post-hoc testing showed that NTS 
drank significantly more than both social-drinking groups (Table 3).  SD-S and SD-NS 
did not differ in amount of alcohol consumed per week (Table 3).  One-way ANOVA 
revealed a main effect of age (p < 0.05):  SD-NS subjects were significantly younger 
than both SD-S and NTS-S subjects (Table 3).  There was a main effect of injected 
radioactivity (p < 0.05).  Post-hoc testing revealed that injected radioactivity in SD-S 
subjects was significantly higher than NTS-S subjects (Table 3).  Mass dose was not 
significantly different across the three groups. 
 
Striatal BPND:  ROI Analysis 
 There was a main effect of group for BPND in the L-pre-DCA, L-pre-DPU, L-post-
DPU, R-pre-DCA, R-pre-DPU, and R-post-DPU (Table 4).  Figure 3 illustrates the 
distribution of BPND in the R-pre-DPU for all three groups.  Although only the R-pre-DPU 
and L-post-DPU survived Bonferroni correction, we observed that the mean BPND values 
for the smoking groups were both lower relative to the non-smokers.  To test the 
hypothesis that BPND is lower in the smokers compared to non-smokers, we performed 
an orthogonal planned contrast within the general linear model framework to compare 
the mean of the SD-NS group to the combined means of the NTS-S and SD-S groups.  
Applying Bonferroni correction to account for multiple comparisons lowered the threshold 
for significance to p < 0.005.  At this corrected significance level, smokers had 
significantly lower striatal BPND values in six regions (Table 5).     
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Table 3.  Subject characteristics.  Data are mean ± s.d. unless otherwise specified.  
Nontreatment-seeking alcoholic smokers:  NTS-S; social-drinking smokers:  SD-S; 
social-drinking non-smokers:  SD-NS.  CWS:  Cigarette Withdrawal Scale. 
* Main effect of group, one-way ANOVA, p < 0.05  
† Different from SD-NS, LSD post-hoc test, p < 0.05 
‡ Different from NTS-S, LSD post-hoc test,  p < 0.05 
 
 
Characteristic  NTS-S (N = 34)  SD-S (N = 21)  SD-NS (N = 26)  
Age*  38.4 ± 8.2†  37.9 ± 8.7†  30.4 ± 7.3  
Education (years)  12.6 ± 2.1  13.0 ± 2.2  14.9 ± 1.7  
Injected radioactivity 
(mCi)* 13.7 ± 1.8 14.8 ± 1.2 14.1 ± 1.1 
Mass dose (nmol/kg) 0.14 ± 0.06 0.13 ± 0.05 0.14 ± 0.09 
Fagerström score  4.35 ± 2.3  4.28 ± 1.4  N/A 
CWS dimension 2 8.53 ± 4.3 7.82 ± 4.0 N/A 
Drinks/wk*  39.7 ± 21  4.80 ± 2.9‡  3.03 ± 2.6‡  
 N (%) N (%) N (%) 
Caucasian  19 (56)  15 (71)  21 (81) 
Male  27 (79)  18 (86)  16 (62)  
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Table 4.  Binding potential values (BPND), all groups.  Nontreatment-seeking alcoholic 
smokers:  NTS-S; social-drinking smokers:  SD-S; social-drinking non-smokers:  SD-NS; 
left/right:  L/R; pre/post-commissural:  pre/post; dorsal caudate:  DCA; dorsal putamen:  
DPU; ventral striatum:  VST.   
* Main effect of group, one-way ANOVA, at p < 0.05, uncorrected 
†  Main effect of group with Bonferroni correction (p < 0.005) 
 
Region BPND 
 NTS-S (N = 34)  SD-S (N = 21)  SD-NS (N = 26)  
 Mean ± SD  Mean ± SD  Mean ±  SD  
L pre-DCA* 2.11 ± 0.34  2.13 ± 0.16  2.29 ± 0.30  
R pre-DCA * 2.11 ± 0.32  2.05 ± 0.20  2.27 ± 0.30  
L post-DCA 1.67 ± 0.34  1.61 ± 0.20  1.70 ± 0.30  
R post-DCA  1.64 ± 0.31  1.53 ± 0.22  1.64 ± 0.32  
L pre-DPU* 2.72 ± 0.30  2.72 ± 0.23  2.94 ± 0.32  
R pre-DPU*, † 2.67 ± 0.32  2.67 ± 0.21  2.92 ± 0.32  
L post-DPU*, † 2.77 ± 0.30  2.77 ± 0.24  3.01 ± 0.33  
R post-DPU* 2.68 ± 0.29  2.71 ± 0.25  2.95 ± 0.37  
L VST 2.18 ± 0.31  2.20 ± 0.26  2.31 ± 0.30  
R VST  2.14 ± 0.39  2.17 ± 0.22  2.19 ± 0.32  
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Figure 3.  Individual BPND data from the right pre-commissural dorsal putamen (R-pre-
DPU), by group.  Blue diamonds:  nontreatment-seeking alcoholic smokers, NTS-S; red 
squares:  social-drinking smokers, SD-S; green triangles:  social-drinking non-smokers, 
SD-NS.  Horizontal lines indicate group means.   
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Table 5.  Binding potential values (BPND) from the region of interest (ROI) analysis, 
stratified by smoking status.  For the purpose of presentation, the smoking group data 
are the mean ± S.D. of all subjects in the NTS-S and SD-S groups.  Left/right:  L/R; 
pre/post-commissural:  pre/post; dorsal caudate:  DCA; dorsal putamen:  DPU; ventral 
striatum:  VST.     
* Groups significantly different at p < 0.05, one-way ANOVA with planned contrasts, 
uncorrected 
† Groups significantly different after correction for multiple comparisons (p < 0.005) 
 
Region BPND 
 Smoking group (N = 55)  
Non-smoking 
group  
(N = 26)  
 Mean ± SD  Mean ± SD  
L pre-DCA* 2.08 ± 0.40  2.29 ± 0.30  
R pre-DCA*  2.08 ± 0.28  2.27 ± 0.30  
L post-DCA 1.65 ± 0.29  1.70 ± 0.30  
R post-DCA  1.60 ± 0.28  1.64 ± 0.32  
L pre-DPU*, †  2.72 ± 0.29  2.94 ± 0.32  
R pre-DPU*, †  2.67 ± 0.28  2.92 ± 0.32  
L post-DPU*, †  2.77 ± 0.27  3.01 ± 0.33  
R post-DPU*, †  2.69 ± 0.27  2.95 ± 0.37  
L VST 2.19 ± 0.29  2.31 ± 0.30  
R VST  2.15 ± 0.33  2.19 ± 0.32  
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Striatal BPND:  Effect of Nicotine Patch Dose 
 To determine if transdermal nicotine patches have an effect on striatal BPND, we 
examined data from three age-matched subsets (n = 7 each) of cigarette smokers.  This 
approach is analogous to that recently reported by Weerts et al. (2013) with  
 [11C]carfentanil.   These subsets included:  (1) smokers who did not receive a nicotine 
patch during the scan day (37.6 ± 7.2 y.o.), (2) smokers who received a patch dose of 7 
or 14mg nicotine (one subject received a 7mg patch, the rest received 14mg; 38.1 ± 10.5 
y.o.), and (3) smokers who received a patch dose of 21mg nicotine (37.0 ± 6.4 y.o.).  
Groups were also balanced for drinking status:  each group contained four SD-S 
subjects and three NTS-S subjects.  One-way ANOVA did not reveal any main effects of 
patch dose on BPND in any of the ten striatal regions, indicating that there was no effect 
of nicotine on BPND (data not shown). 
 
ROI volumes:  Group differences 
 There was a main effect of group on ROI volume in the L-pre-DCA, L-pre-DPU, 
L-post-DCA, R-pre-DCA, R-pre-DPU, and R-post-DCA (Table 6).  Post-hoc testing 
revealed that, regardless of smoking status, ROI volumes for both social-drinking groups 
(SD-S and SD-NS) were significantly greater than those for the NTS-S group in several 
regions (Table 6). 
 
Discussion 
 
 The current study investigated whether chronic abuse of both alcohol and 
tobacco cigarettes has a differential effect on D2/D3 receptor availability compared to 
what has been previously reported for alcohol or tobacco-cigarette dependence alone 
(Busto, 2009; Fehr, 2008; Martinez, 2005; Volkow, 1996).  The major result of this study 
was that cigarette smoking was associated with lower RAC BPND, independent of 
drinking status.   
The finding that cigarette smoking is associated with low RAC BPND is in line with 
previous studies that reported lower D2/D3 receptor availability in chronic cigarette 
smokers relative to non-smokers (Busto, 2009; Fehr, 2008; Stokes, 2011).  However, the 
current results are inconsistent with data from Martinez et al. (2005) which documented 
reduced striatal D2/D3 receptor availability in detoxified alcoholic subjects, even with 
matching control subjects for smoking status, as we did in the present study.   
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Table 6.  Region of interest (ROI) volumes, all groups.  Nontreatment-seeking alcoholic 
smokers:  NTS-S; social-drinking smokers:  SD-S; social-drinking non-smokers:  SD-NS; 
left/right:  L/R; pre/post-commissural:  pre/post; dorsal caudate:  DCA; dorsal putamen:  
DPU; ventral striatum:  VST.   
* Main effect of group, p < 0.05, uncorrected 
† Different from SD-S, LSD post-hoc test, p < 0.05 
‡ Different from SD-NS, LSD post-hoc test, p < 0.05 
 
 
Region Volume (cm3) 
 NTS-S (N = 34)  SD-S (N = 21)  SD-NS (N = 26)  
 Mean ± SD  Mean ± SD  Mean ±  SD  
L pre-DCA* 3.10 ± 0.58†, ‡ 3.50 ± 0.63 3.44 ± 0.46 
R pre-DCA*  3.35 ± 0.52†, ‡ 3.81 ± 0.52 3.73 ± 0.49 
L post-DCA* 0.59 ± 0.16†, ‡ 0.72 ± 0.21 0.72 ± 0.22 
R post-DCA*  0.55 ± 0.14†, ‡ 0.68 ± 0.19 0.68 ± 0.21 
L pre-DPU* 2.23 ± 0.31†, ‡ 2.45 ± 0.23 2.36 ± 0.31 
R pre-DPU* 2.52 ± 0.30†, ‡ 2.75 ± 0.25 2.71 ± 0.31 
L post-DPU 2.69 ± 0.43 2.80 ± 0.35 2.69 ± 0.44 
R post-DPU 2.53 ± 0.42 2.63 ± 0.31 2.52 ± 0.44 
L VST 0.60 ± 0.09 0.65 ± 0.06 0.64 ± 0.11 
R VST  0.62 ± 0.08 0.67 ± 0.06 0.67 ± 0.11 
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In other studies of D2/D3 receptor availability in alcoholics, imbalances in smoking 
status between alcoholics and controls may have accounted for some reported lower 
D2/D3 receptor availability in alcoholics (Heinz, 2004; Hietala, 1994; Volkow, 1996; 
Volkow, 2002).  An important difference between the current and previous studies is that 
we sampled nontreatment-seeking alcoholics from the local community, whereas prior 
work studied abstinent alcoholics after inpatient detoxification.  These are likely two 
distinct populations of alcohol-dependent subjects.  Treatment-seeking alcoholics have 
more severe alcoholism than nontreatment-seekers (Fein, 2005), have a higher 
comorbidity of psychiatric disorders (Di Sclafani, 2008), and a greater degree of gray 
and white matter abnormalities (Gazdzinski, 2008).  Thus, it is possible that individuals 
from a community-based, currently heavy-drinking (and smoking) population may not 
have apparent deficits in striatal D2/D3 receptor availability when compared to social-
drinking controls matched for cigarette smoking status.     
 Because BPND is a compound index (Bavail/KD), lower striatal BPND in smokers 
relative to non-smokers could be interpreted as either lower numbers of D2/D3 receptors, 
or higher synaptic/extrasynaptic DA concentration.  We speculate that cigarette smoking 
produces an apparently lower D2/D3 availability via increased striatal DA concentration. 
This would be consistent with a post-mortem study of chronic cigarette smokers, which 
reported that DA levels in smokers’ striatal tissue were significantly higher compared to 
non-smokers, whereas D2 and D3 receptor levels were not different between groups 
(Court, 1998).  It is possible that smoking-induced increases in striatal DA occur through 
inhibition of monoamine oxidase (MAO).  Dopamine is a substrate for both MAO 
isoforms (MAO-A and -B), and chronic treatment with either MAO-A or MAO-B inhibitors 
increases basal striatal DA (Kaseda, 1999; Lakshmana, 1998; Lamensdorf, 1996).  
Several studies established that platelet MAO activity is lower in current cigarette 
smokers relative to non-smokers and former smokers (Berlin, 1995; Norman, 1987; 
Oreland, 1981).  Multiple PET studies have demonstrated inhibition of both MAO 
isoforms (MAO-A and -B) in the brains of smokers (Fowler, 1996a; Fowler, 1996b; 
Leroy, 2009).  Cigarette smoke itself is a potent inhibitor of both MAO isoforms (Yu, 
1987), and several of the inhibitory compounds in cigarette smoke extract have been 
identified, including the β-carbolines harman and norharman (Herraiz, 2005).  
Collectively, this body of evidence strongly supports the possibility that cigarette smoke 
increases DA levels, resulting in apparent lower striatal RAC D2/D3 availability in 
smokers.          
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 Alternatively, it is possible that the nicotine patches worn by a majority of 
subjects induced DA release.  All but seven smokers were administered nicotine patches 
on the scan day, and studies in the animal literature suggest that nicotine itself may 
cause measurable DA release (Nisell, 1994; Schiffer, 2001).  Three human RAC studies 
found similar results (Brody, 2006; Brody, 2004; Takahashi, 2008).  However, in the two 
Brody et al. studies, the designs included subjects physically smoking while inside the 
scanner, and it is possible that the chemosensory properties of smoking a cigarette are 
central factors contributing to the DA release observed in these studies.  In fact, recent 
data support this possibility:  Domino et al. (2012) showed that smoking denicotinized 
cigarettes causes measurable DA release, indicating that the presence of nicotine may 
not be a necessary condition for increased DA during the act of smoking.  Although 
Takahashi et al. (2008) reported that chewing nicotinized gum increased striatal DA in 
cigarette smokers, the design included a placebo condition as the “baseline”.  If the 
placebo condition induced a negative prediction error (nicotine expected from the gum, 
but not delivered), this could have induced a decrease in striatal DA (Yoder et al., 2009) 
during the placebo condition, producing results that show an apparent “increase” in DA 
during the nicotinized gum condition (see discussion of design confounds in Yoder et al. 
(2011c)).  There is also strong pharmacological evidence that nicotine itself does not 
induce DA release measurable by RAC PET.  When nicotine was administered 
intranasally to humans and intravenously to unanesthetized monkeys, there were no 
significant reductions in RAC binding (Montgomery, 2007; Tsukada, 2002).  Finally, our 
data did not show any evidence of a measurable effect of nicotine patches on BPND.  
Therefore, we suggest that it is unlikely that the use of nicotine patches was a significant 
confound in this study.        
  There are limitations to this retrospective study.  As all of our alcoholic subjects 
were also cigarette smokers, we could not assess the specific contributions of alcohol 
and cigarette use to D2/D3 availability in this sample.  Inclusion of a group of non-
smoking alcoholics would be needed to confirm the conclusion that the group differences 
observed in the current study were due solely to chronic smoking.  Also, although every 
effort was made to screen for use of illicit substances, some subjects tested positive for 
drugs besides marijuana (2 for cocaine, 2 for opiates) on the day of scanning.  
Examination of these subjects’ data indicated that the BPND values were well within 2 
standard deviations of the group mean, indicating that they were not outliers skewing the 
results.  A history of substance abuse or dependence was an exclusion criteria; 
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however, we cannot preclude the possibility that prior recreational use of other illicit 
substances contributed variance to the data.  The reduced striatal volumes in the NTS-S 
group introduces another potential confound, via the risk of partial volume effects on 
BPND (Morris, 2004).  NTS-S subjects had smaller striatal volumes (Table 6) than the 
other two social drinking groups, but there were no differences in striatal RAC BPND 
between the alcoholic smokers and social drinking smokers.  If striatal atrophy (and 
hence, partial volume effect) was the sole source of apparent lower BPND between 
smokers and non-smokers, then we might expect similar levels of atrophy in both 
smoking groups.  However, this was not the case.  Therefore, we suggest that striatal 
atrophy in the alcoholic smokers is an unlikely source of significant variance in our data.  
Another potential concern is the significantly younger age of the SD-NS subjects 
compared to the SD-S and NTS-S subjects (Table 3).  Age-related decline of striatal 
D2/D3 receptor availability is well-documented, with estimates ranging from 4-8% 
decrease per decade (for comprehensive review, see Ishibashi, 2009).  However, the 
majority of such studies were conducted with a very wide age range (e.g., from 20-80 
years of age) in healthy individuals.  In the present work, we did not observe a 
correlation between BPND and age in either social drinking group, perhaps because of 
the limited age range of our samples.  However, we did observe a correlation between 
age and BPND in the smoking alcoholic group (data not shown).  Because age was not 
uniformly related to BPND across our samples, we believed it was not appropriate to use 
age as a covariate in the data analyses.  Our observations of age-related decline in 
BPND in NTS-S (especially in a sample with a restricted age range) is consistent with  
recent evidence, which suggests that  this decline may be accelerated in certain 
populations such as schizophrenia (Kegeles, 2010) and alcoholism (Rominger, 2012a). 
In conclusion, the primary finding in the present study is that, regardless of 
drinking status, cigarette smokers have lower striatal D2/D3 receptor availability 
compared to non-smokers.  This is important, as it suggests that some component(s) of 
cigarette smoke may act on the dopamine system independently of alcohol abuse.  This 
adds to the growing literature demonstrating the adverse effects of cigarette smoking on 
brain structure and chemistry (for review, see Durazzo, 2007).  Additionally, recent 
findings indicate that continued cigarette use during treatment for substance abuse may 
be detrimental to clinical outcome  (for review, see Kalman, 2010).  Although it is 
tempting to speculate that the effects of cigarette smoking on brain dopamine may 
interfere with treatment for alcoholism and other addictions, more research is needed to 
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explore this possibility.  In addition to studying the clinical implications of smoking on 
D2/D3 availability, future studies must address the molecular ramifications of chronic 
cigarette abuse on the dopamine system.    
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Chapter 3:  Cortical dopamine release during a behavioral response inhibition task 
 
 This chapter explores the use of [18F]fallypride to determine whether cortical DA 
release during a response inhibition task can be detected with current PET methods.  
This pilot, proof-of-principle study was conducted in nine healthy males.  On separate 
days, subjects received one [18F]fallypride scan during a “Go” control task and one 
[18F]fallypride scan during a response inhibition task (stop-signal task).  Parametric BPND 
images were generated and analyzed with SPM8.   
Results from the voxel-wise analysis indicated significant SST-induced DA 
release in several cortical regions involved in inhibitory control, including the insula, 
cingulate cortex, orbitofrontal cortex, precuneus, and supplementary motor area.  The 
regions reported as having significant task-induced DA changes have been consistently 
observed in fMRI studies to be activated during response inhibition.  There was also a 
significant positive correlation between DA release in the left orbitofrontal cortex, right 
middle frontal gyrus, right precentral gyrus, and stop-signal reaction time.  These data 
support the feasibility of using [18F]fallypride PET to study DA release during a response 
inhibition task.  Future work will use this paradigm to investigate the relationships 
between DA function and impulsive behavior.   
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Introduction 
 
Impulsive behaviors are a hallmark of several forms of psychopathology, 
including addiction (Jentsch, 1999), as addicts are often unable to restrain the impulse to 
pursue and consume addictive substances even in the face of detrimental 
consequences.  There are many facets of impulsivity that are relevant for addiction 
(Evenden, 1999; Perry, 2008), but one of the most frequently-studied aspects is motor 
inhibition, which is often characterized by the ability to inhibit a prepotent response.  
Impaired performance on motor inhibition tasks is a common characteristic across 
addicted and at-risk populations (e.g. Courtney, 2013; Goudriaan, 2006; Li, 2009; Nigg, 
2006).  Motor response inhibition is often indexed with stop signal reaction time (SSRT) 
as derived from the stop signal task (SST).  SSRT is defined as the time required to 
withdraw (Stop) a ballistic hand movement (Logan, 1994; Logan, 1984).  Specifically, 
subjects are required to respond quickly to “Go” stimuli, with intermittent “Stop” stimuli 
signaling the need to withhold that motor response.  Subjects with impaired motor 
inhibition are less able to inhibit their motor response, and thus have longer SSRTs 
(Lipszyc, 2010).   
A number of human functional magnetic resonance imaging (fMRI) studies 
suggest that successful response inhibition, as indexed by SSRT, is strongly associated 
with the blood oxygen level dependent (BOLD) signal in a network of fronto-basal 
ganglia circuitry (Aron, 2006; Chambers, 2006; Congdon, 2010), particularly in the 
inferior frontal cortex (IFC), anterior insula (AI), anterior cingulate cortex (ACC), 
presupplementary motor area (pre-SMA), subthalamic nucleus (STN), globus pallidus 
(GP), and putamen (PUT).  Dopamine (DA) is a neurotransmitter that is critical for 
modulating activity in many of these regions (Frank, 2005).  Additionally, a growing body 
of evidence suggests that cortical dopaminergic neurotransmission plays a substantial 
role in mediating impulsive behavior, both generally, and specifically with respect to 
motor response inhibition.  Animal studies have demonstrated increases in frontal DA 
during an impulsive choice task (delay-discounting) (Winstanley, 2006).  Selectively 
altering frontal DA concentrations via lesions increases impulsive choice (Kheramin, 
2004), whereas pharmacologically-increased DA reduces impulsive choice (Robinson, 
2008), as indicated by shifts in discounting.  St. Onge et al. (2011) also recently reported 
that prefrontal cortex (PFC)-specific blockade of D2 receptors increased risky choice in 
rats.  In humans, evidence for a link between cortical dopaminergic transmission and 
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impulsivity is gradually emerging, and several lines of evidence are converging to 
support such a relationship.  Catechol-O-methyltransferase (COMT) is the enzyme 
responsible for the majority of dopamine catabolism in the frontal cortex (Chen, 2004).  A 
recent human study found that treatment with tolcapone, a COMT inhibitor, was 
associated with less impulsive choice, presumably via decreases in frontal cortical DA 
(Kayser, 2012).  In line with this, Boettinger et al. (2007) reported that human subjects 
with a more active form of COMT display relatively higher impulsive behavior.  Taken 
together, these preclinical and human reports have been instrumental in highlighting the 
importance of dopaminergic signaling in impulsive behavior.  However, it is important to 
note that many of the above studies employed measures of impulsivity distinct from the 
stop signal paradigm.  Although some facets of impulsivity are likely related across 
different operational definitions, there is evidence to suggest a disconnect between 
certain impulsive measures, such as the delay discounting and stop signal tasks (Dalen, 
2004; De Wit, 2009; Solanto, 2001).  Thus, the specific processes by which DA 
modulates human motor response inhibition processes are still largely unknown.  
Human and small animal studies attempting to elucidate the neuropharmacology 
of SST performance have yielded equivocal results.  Several studies reported that 
atomoxetine (ATM), a selective norepinephrine (NE) reuptake inhibitor, improves SSRT 
in both humans (Chamberlain, 2009; Chamberlain, 2006) and small animals (Bari, 2009; 
Bari, 2011; Robinson, 2008).  Furthermore, although atomoxetine increases both cortical 
DA and NE (Bymaster, 2002), its ability to improve SSRT was shown to be unaffected by 
cortical DA blockade (Bari, 2011).  In contrast, D2-specific blockade in the dorsal striatum 
was shown to selectively impair SST performance (i.e. increase SSRT, Eagle, 2011).  In 
a human study, Nandam et al. (Nandam, 2011) reported that the DA transporter blocker 
methylphenidate (MP), but not ATM, improved SSRT.  Similarly, in a separate human 
study, the D2-specific agonist cabergoline improved SSRT, without affecting overall 
reaction time (Nandam, 2013).  These discrepancies across the literature indicate that 
motor response inhibition is likely under control of several neurotransmitter systems, 
although interpretation is likely complicated by inter-species differences in anatomy and 
neurotransmission, as well as the complexity of the cognitive process.        
To date, there has been only one comparison of SST performance with an in vivo 
measure of dopamine receptor availability (Ghahremani, 2012), which found significant 
correlations between baseline dorsal striatal D2/D3 receptor availability and SSRT (as 
derived from performance outside the scanner).  Furthermore, the authors reported that 
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baseline dorsal caudate D2/D3 receptor availability was correlated with the BOLD signal 
during SST in the dorsal caudate and several frontal cortical regions (e.g. ACC, IFG, 
OFC).  However, while this investigation provided novel evidence linking SST 
performance to baseline striatal dopamine D2/D3 receptor availability, the role of cortical 
dopaminergic neurotransmission during the performance of a behavioral response 
inhibition task remains unclear.  In an attempt to address this issue, we conducted an 
proof-of-principle study in healthy subjects to determine whether changes in D2/D3 
receptor availability (indicative of changes in dopamine) during a SST could be detected 
using positron emission tomography (PET) and [18F]fallypride (FAL).  Subjects were 
scanned under two conditions:  one during performance of a SST, and one during 
performance of a control attention task requiring only “Go” responses.  We hypothesized 
that the SST would induce changes in dopamine in cortical regions similar to those 
reported in BOLD fMRI studies of response inhibition.          
 
Methods 
 
 All study procedures were approved by the Indiana University Institutional 
Review Board and performed in accordance with the ethical standards of the Belmont 
Report.  Subjects were recruited by local advertising in the greater Indianapolis area.  
Written informed consent was obtained after the study was completely described to the 
subjects.  Nine healthy, right-handed, adult men completed study procedures.  Subjects 
underwent a screening interview that included the Edinburgh handedness inventory 
(Oldfield, 1971), a 30-day Time Line Follow Back (TLFB; Sobell, 1986) calendar for 
recent drinking, and the Alcohol Use Disorder Identification Test (AUDIT; Saunders, 
1993) to screen for risky drinking behavior.  Exclusion criteria were:  age less than 18 or 
greater than 45 years of age, contraindications for MRI, current use of medications with 
central nervous system action, current use of tobacco or recreational drugs, 
consumption of ≥ 15 drinks per week, or > 4 drinks on one occasion, AUDIT scores > 8, 
reported history of neurological and/or psychiatric disorders, and a positive urine 
toxicology screen (Q-10, Proxam) as administered at screening, and on the day of PET 
imaging.  Subjects received two [18F]fallypride (FAL) PET scans, conducted on separate 
days, and with scan order counterbalanced across subjects.  The baseline FAL scan 
was acquired while subjects performed a control attention task.  The challenge FAL scan 
was acquired during performance of a behavioral response inhibition task (stop signal 
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task, SST).  Initiation of the tasks began five minutes prior to FAL injection.  Individual 
task presentation lasted for ~6 minutes.  Tasks were presented four times in a row with a 
~5 min break between runs.  Total task time was ~45 min.  During breaks and after 
completion of the final tasks, a fixation cross was displayed to help maintain subject 
wakefulness.  Tasks were presented to subjects on a computer monitor situated outside 
the gantry.  The monitor screen was fully visible to the subject.  Prior to tracer injection, 
study personnel ensured that the subject was able to easily see, read, and perform the 
task without significant head movement.  Task responses were made via a wireless 
mouse that was placed on a table adjacent to the scanner bed; tray table position was 
adjusted for a comfortable height and distance for the subject.  Both “Go” and SST tasks 
were modified versions used by Kareken et al. (2013) and programmed in E-prime 2.0 
software (Psychology Software Tools Inc., Sharpsburg, PA). 
 
Stop-signal task 
 Four SST task runs were presented to the subjects.  Each SST run consisted of 
a combination of 80 “Go” trials and 40 “Stop” trials.  During “Go” trials, subjects were 
presented with horizontal blue arrows that pointed left or right.  Subjects were instructed 
to press the “left” mouse button for a left arrow, and the “right” mouse button for a right 
arrow.  Subjects were instructed to respond as quickly and accurately as possible.  
“Stop” trials consisted of a red “up” arrow that appeared immediately after a blue arrow 
presentation.  Subjects were instructed that, when they saw the red arrow, they were to 
withhold their response to the immediately preceding blue arrow.  Across stop trials, an 
adaptive staircase algorithm adjusted the temporal delay between “Go” and “Stop” 
stimuli in 50 ms increments, to achieve a target “Stop” inhibition rate of 50%.  That is, for 
each run, the “Stop” signal delay (SSD) time was set initially at 250 ms, and then either 
increased or decreased by 50 ms after successful or failed “Stop” response, 
respectively.  SSD was programmed to be between 0 ms and 1450 ms.  For each 
subject, average SSD was computed across all four runs, using only the data after the 
point at which the subject successfully converged to 50% stop inhibition.  The mean, 
median, and standard deviation of reaction time on “Go” trials were calculated only for 
“Go” trials in which participants responded correctly.  In order to calculate stop signal 
reaction time (SSRT), all Go-RTs were arranged from smallest to largest.  The average 
SSD was then subtracted from that subject’s xth percentile “Go” RT, where x 
corresponds to the stop failure rate (Band, 2003).  Thus, if a subject successfully 
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inhibited their response on 55% of “Stop” trials, the Go-RT corresponding to the 55th 
percentile of the subject’s Go-RT distribution would then be selected, and the average 
SSD subtracted from this Go-RT to yield SSRT.   
 
Go attention task 
 During “Go” trials, subjects were presented with horizontal blue arrows that 
pointed left or right.  Subjects were instructed to press the “left” mouse button for a left 
arrow, and the “right” mouse button for a right arrow.  Subjects were instructed to 
respond as quickly and accurately as possible.   
 
Image Acquisition  
 A magnetized prepared rapid gradient echo (MP-RAGE) magnetic resonance 
image (MRI) was acquired using a Siemens 3T Trio-Tim for anatomic coregistration and 
processing of PET data.   [18F]fallypride (FAL) was synthesized at the Department of 
Radiology and Imaging Sciences radiochemistry facilities in the Biomedical Research 
Training Center, according to previously described methods (Gao, 2010).  FAL PET 
scans were acquired on an ECAT HR+ (3D mode; septa retracted).  FAL PET scans 
were initiated with an IV infusion of 170.63 ± 33.4 MBq FAL over the course of 1.5 
minutes.  Injected mass was 0.052 ± 0.03 nmol/kg.  The dynamic PET acquisition was 
split into two segments for subject comfort (Christian, 2006).  The first half of dynamic 
acquisition was 60 min (6 x 30s, 7 x 60s, 5 x 120s, 8 x 300s).  Following this segment, 
the subject was removed from the scanner for a ~15 min break period to stretch and use 
the restroom if needed.  The second half of dynamic acquisition lasted 50 min (10 x 
300s). 
 
Image Processing 
 Dynamic PET data were reconstructed with Siemens ECAT software, v7.2.2.  
Three-dimensional data were rebinned into 2D sinograms with Fourier rebinning.  
Sinograms were corrected for randoms, scatter, and attenuation, and images were 
generated with filtered back-projection with a 5mm Hanning filter.  MRI and dynamic 
PET images were converted to Neuroimaging Informatics Technology Initiative (NIfTI) 
format (http://nifti.nimh.nih.gov/) and processed with SPM8.  A mean PET image that 
contained a mixture of blood flow and specific binding was created using the realignment 
algorithm.  This mean PET was coregistered to the subject’s anatomic MRI using the 
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mutual information algorithm in SPM8.  Each frame of PET data was subsequently 
coregistered to the MRI-registered mean PET image to correct for subject motion.  Each 
subject’s MRI was spatially normalized to Montreal Neurological Institute (MNI) space 
and the transformation matrix obtained from the spatial normalization step was then 
applied to the motion-corrected PET data from each subject.  
 
Voxel-wise Analysis      
Dopamine (DA) D2/D3 receptor availability was indexed with binding potential 
relative to nondisplaceable binding  (BPND), which is operationally defined as fND*Bavail/KD 
(Innis, 2007).   The cerebellum (vermis excluded) was used as the reference region 
(tissue that contains few to no D2/D3 receptors).  Individual gray matter cerebellar 
regions of interest (ROIs) were created for each subject in order to extract cerebellar 
time activity curves.  BPND was estimated at each brain voxel with Logan reference 
graphical analysis (Logan, 1996) using the cerebellar time activity curve as in input 
function.  t* was set at 25 data points in “stretched” time.  The resulting parametric BPND 
images were smoothed with an 8mm Gaussian kernel (Costes, 2005; Picard, 2006; 
Ziolko, 2006).  In areas of high D2/D3 receptor density, like the striatum, > 2.5 hours of 
scanning is required to accurately estimate BPND (Christian, 2006; Christian, 2000).  As 
subjects in our study were scanned for approximately 2 hours, we implemented a gray 
matter mask to exclude the striatum.  In addition, parametric BPND image voxels with 
very low values (< 0.1) were excluded from further analysis to ensure that only reliably 
estimated BPND values from both scans were considered.     
 
Statistical Analysis 
 Voxel-wise, one-tailed paired t-tests were used to detect significant changes in 
FAL BPND between scan conditions.  Tests were run in both directions to test for both 
increases and decreases in BPND during the SST relative to the attention task condition.  
Significant clusters were defined at p < 0.005 (uncorrected) and cluster size k > 10 
voxels.  Each significant cluster was defined as a region of interest (ROI), and average 
regional BPND  values were extracted from the  “Go” baseline and SST parametric 
images with the MarsBaR toolbox (http://marsbar.sourceforge.net/).  This allowed us to 
calculate percent change in BPND:  (%∆BPND) = ((BPND, GO – BPND, SS)/BPND, GO )* 100 for 
each cluster, and to test for bivariate correlations with SSRT using SPSS 20.0.  Data 
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from significant regression analyses were tested for outliers using Cook’s D (Bollen, 
1985).  Data are presented as mean ± s.d., unless otherwise specified.   
 
Results 
 
Subject Characteristics 
 Subjects were 24.6 ± 4.1 years old (range 19 – 32), and had 15.7 ± 1.3 years of 
education.  All subjects were light social-drinkers:  average alcohol consumption was 
1.91 ± 2.5 drinks per week; AUDIT scores were 3.0 ± 1.7.     
 
Task performance 
 Behavioral results from the “Go” control attention task and SST are shown in 
Table 7.  Data for the “Go” task from one subject was unavailable because of computer 
failure.  Behavioral SST data from two subjects were excluded because they failed to 
converge to 50% stop inhibition throughout the course of the task. 
 
Changes in FAL BPND during the Stop Signal Task 
 Voxel-wise paired t-tests revealed several cortical regions where BPND during the 
SST (BPND, SS) was significantly lower than BPND during the “Go” attention task (BPND, GO) 
(Figure 4, Table 8), indicative of dopamine (DA) release in these regions during the SST.  
BPND, GO was significantly lower than BPND, SS in the anterior cingulate gyrus (Figure 5, 
Table 8), indicative of decreased DA in this region during the SST.   
 
Association between ∆BPND and Stop Signal Task performance 
  Of the 21 extracted clusters in which there was a significant change in BPND 
(Figures 4 – 5, Table 8), ∆BPND significantly negatively correlated with SSRT (n = 7) in 
the left orbitofrontal cortex (OFC; r = -0.842, p = 0.017), right middle frontal gyrus (MFG; 
r = -0.833, p = 0.020), and right precentral gyrus (r = -0.877, p = 0.009).  None of the 
data points in any of the three regressions met the criteria as undue influence points, 
which was defined by threshold D < 0.57.  D-value ranges were:  L-OFC, 0.000 – 0.268; 
R-MFG, 0.017 – 0.432; R-precentral gyrus, 0.015 – 0.403.  
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Table 7. Performance on the “Go” attention task and Stop Signal task. Data are mean ± 
s.d.  RT, reaction time; SSRT, stop signal reaction time, 
    
”Go” task performance (n = 8) 
Correct trials (%) 98.5 ± 1.4 
Median Go-RT (ms)  378 ± 45 
Stop Signal task performance (n = 7) 
Correct “Go” trials (%) 96.5 ± 7.6 
Correct “Stop” trials (%) 56.3 ± 9.5 
Median Go-RT (ms) 577 ± 140 
SSRT (ms) 232 ± 23 
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Table 8.  Voxel-wise results of changes in dopamine (DA) during the SST.  Regions of 
increased DA were taken from the BPND, BL > BPND, SS contrast.  Regions of decreased 
DA were taken from the BPND, SS > BPND, BL contrast.  MNI, Montreal Neurological 
Institute; k, cluster size; STG, superior temporal gyrus; IPL, inferior parietal lobe; SMG, 
supramarginal gyrus; SMA, supplementary motor area; ITG, inferior temporal gyrus; 
MFG, middle frontal gyrus; SFG, superior frontal gyrus; IFG, inferior frontal gyrus; OFC, 
orbitofrontal cortex; ACC, anterior cingulate cortex.  Statistical threshold was p < 0.005, 
uncorrected, k > 10 voxels. 
     
Region/cluster 
MNI Coordinates Cluster 
Size 
(k) 
Peak voxel         
(Z-score) 
%∆BPND 
Mean ± SD x y z 
Regions of increased DA 
Precuneus -8 -62 36 141 3.52 10.2 ± 5.7 
 14 -58 62 33 3.30 15.2 ± 12 
Cingulate cortex 4 -20 40 14 3.34 5.9 ± 3.6 
 10 12 42 22 3.00 9.3 ± 6.5 
 -10 -12 40 11 2.81 6.5 ± 4.0 
IPL/SMG 64 -36 34 28 3.33 12.1 ± 3.8 
SFG/SMA -10 4 58 23 3.28 8.2 ± 5.2 
Fusiform gyrus -28 -50 -16 25 3.21 5.9 ± 4.0 
 -40 -38 -26 45 3.12 15.5 ± 11 
STG 60 -50 14 21 3.18 6.5 ± 5.0 
 62 -36 12 51 3.06 17.1 ± 8.3 
Angular gyrus 50 -62 30 26 3.15 7.1 ± 5.0 
Paracentral lobule 6 -32 68 22 3.06 11.6 ± 9.0 
Postcentral gyrus 62 -14 16 85 3.01 8.2 ± 5.4 
MFG 30 10 44 37 2.99 19.0 ± 15 
 20 -16 64 22 2.77 24.8 ± 19 
 36 24 48 26 3.34 11.2 ± 8.2 
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OFC/IFG -22 14 -28 13 3.00 6.80 ± 4.1 
Precentral gyrus 46 -10 32 22 2.81 16.2 ± 13 
Uncus  -32 -14 -38 10 3.01 14.5 ± 10 
Regions of decreased DA 
ACC  -2 30 -4 16 3.13 -33.9 ± 32 
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Figure 4.  Whole-brain voxel-wise paired t-test comparing BPND between baseline “Go” 
and SST scan conditions (n = 9).  The “hot” colorscale indicates voxels where BPND, BL 
was significantly higher than BPND, SS (increased DA during SST).  Display threshold p < 
0.005, uncorrected, k > 10.  Significant clusters are listed in Table 8. 
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Figure 5.  Whole-brain voxel-wise paired t-test comparing BPND between baseline “Go” 
and SST scan conditions (n = 9).  The “cool” colorscale indicates voxels where BPND, SS 
was significantly higher than BPND, BL (indicating decreased DA during SST).  Display 
threshold p < 0.005, uncorrected, k > 10.  Significant clusters are listed in Table 8. 
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Discussion 
 
 The principle finding of the current study is that changes in cortical D2/D3 receptor 
availability were detectable during a stop signal task (SST) relative to a control attention 
task.  To our knowledge, this is the first demonstration of in vivo changes in cortical DA 
during a motor response inhibition task.  The anatomic locations of significant clusters of 
∆BPND correspond well to neural correlates of inhibiting motor responses that have been 
characterized in humans with fMRI (Aron, 2006; Chambers, 2009; Congdon, 2010).  
These, and other reports, have emphasized the importance of the IFC, SMA, pre-SMA, 
ACC, STN, and striatum in successful response inhibition (Zandbelt, 2010).  While fMRI 
provides excellent spatial localization and has good temporal sampling ability, other in 
vivo techniques such as PET are needed to elucidate the specific neurochemical 
substrates of the SST.  Using [18F]fallypride (FAL) PET, we demonstrated SST-induced 
changes in dopaminergic signaling in several cortical regions that are implicated in 
behavioral response inhibition.  In particular, we observed significant increases in DA in 
motor-related brain regions such as the SMA and precentral gyrus (Figure 4, Table 8), 
which are thought to be crucial regions in the stopping process (Floden, 2006; Li, 2006).  
Other cortical regions that exhibited significant SST-induced changes in DA have 
previously been shown to activate during SST performance, including frontal (middle and 
superior frontal gyri), parietal (precuneus, paracentral lobule, postcentral gyrus 
supramarginal gyrus, angular gyrus), temporal (fusiform gyrus, superior temporal gyrus) 
and cingulate cortex areas (Cai, 2009; Congdon, 2010; Courtney, 2013; Ghahremani, 
2012; Kareken, 2013).   
The precuneus is one of the core regions of the “default mode network” (DMN; 
Bressler, 2010), which engages in the absence of a directed task and is believed to 
mediate “switching” cognitive processes on and off (Li, 2007; Zhang, 2010).  
Dopaminergic transmission affects precuneus activity during cognitive task performance.  
For example, Argyelan et al. (2008) showed that cognitively-induced change in 
precuneus activity was affected by a DA agonist.  Tomasi et al. (2009) found that 
deactivation of the precuneus during a visuospatial attention task was negatively 
associated with striatal dopamine transporter availability.  The SST-related increases in 
dopamine in the precuneus that were observed in this study may indicate a role for 
dopamine in deactivating the DMN in order to engage processes relevant for motor 
response task performance.                   
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 In the present analysis, we also report that task-induced changes in D2/D3 
receptor availability were negatively correlated with SSRT in three cortical subregions, 
the left orbitofrontal cortex, right middle frontal gyrus, and right precentral gyrus (Table 
8).  These regions have been identified as belonging to a common network that exhibits 
SST-induced activation, in which activation was also significantly associated with SSRT 
(Congdon, 2010).  Another fMRI study confirmed that SST-induced BOLD responses in 
these regions were associated with SSRT (Ghahremani, 2012).  These reports lend 
support to our interpretation of the present data, which is that cortical dopamine in these 
regions may contribute to performance of a motor response inhibition task.  However, 
the literature on the cortical neurochemistry and neuroanatomy underlying motor 
inhibition performance is admittedly more complicated.    
 Human imaging studies have not definitively discerned the precise locations and 
neurotransmitter systems relevant for response inhibition.  There is much debate over 
which specific brain regions are important for stopping a motor response.  While 
numerous studies cite the IFC as an essential locus for successful inhibition (Aron, 2003; 
Swick, 2008), there is also evidence supporting the OFC (Horn, 2003), and precentral 
gyrus (Li, 2006) as neural hubs for response inhibition modulation.  A recent fMRI study 
in adolescents reported differential activation of brain networks during a SST that was 
dependent on substance abuse and ADHD phenotypes (Whelan, 2012).  This suggests 
that interindividual variability may affect which specific brain regions are recruited for 
task performance.   
 Global manipulations of DA function provide indirect evidence about 
dopaminergic regulation of brain activity during impulse control.  Administration of a DA 
agonist increases regional cerebral blood flow (rCBF) in the OFC and precentral gyrus, 
and decreases rCBF in the MFG (Bradberry, 2012), indicating that activity in these 
regions is under control of DA transmission.  During motor inhibition tasks, DA 
perturbation has similar effects on brain activity.  DA antagonism results in decreased 
activation of the precentral gyrus during a motor inhibition task (Luijten, 2013).  
Conversely, increasing brain DA levels leads to increased activation of MFG and 
precentral gyrus during a SST (Li, 2010).  Furthermore, the change in MFG activation is 
positively correlated with improvement of SSRT, suggesting that DA may be an 
important modulator of MFG activity during SST performance.  Overall, the data from the 
literature, combined with that from the current study, suggest that the association of 
OFC, MFG, and precentral gyrus activation with performance on a response inhibition 
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task may be modulated, in part, by DA.  However, replication of these results in a larger 
cohort is necessary to further understand these associations. 
  The present study has several limitations.  The sample size is relatively small, 
and thus presents a risk of both Type I and Type II errors.  We readily acknowledge that 
this is a preliminary analysis, and replication in a larger sample is needed to support our 
interpretations.   However, task-induced DA changes in this study overlap well with 
regions that have been demonstrated to elicit BOLD responses during a stop signal task 
(Aron, 2006; Chambers, 2009; Congdon, 2010).  This suggests that our findings are 
physiologically relevant and not merely the result of a Type I error.  Another potential 
limitation of the current study is that we did not examine the striatum.  Ghahremani et al. 
(2012) recently reported that baseline striatal D2/D3 receptor availability was negatively 
correlated with SSRT.  Additionally, several fMRI studies have shown striatal activation 
during successful response inhibition (Congdon, 2010; Vink, 2005; Zandbelt, 2010).  
However, because we were primarily interested in cortical DA, our study design used a 
2-hour scan:  long enough to accurately estimate cortical, but not striatal BPND.        
 In conclusion, we detected significant changes in cortical D2/D3 receptor 
availability during a stop signal task compared to a control attentional task.  Percent 
change in receptor availability was correlated with task performance in three cortical 
regions that have been shown to be important for successful response inhibition.  The 
present results demonstrate the feasibility of using [18F]fallypride PET to detect changes 
in DA during a stop signal challenge, and the potential to use the SST as a probe for 
studying cortical dopaminergic contributions to disorders marked by impulsive behavior. 
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Summary 
 
 The results of this report highlight the utility of PET imaging as a tool for probing 
the DA system in addicted populations and addiction phenotypes.  This technique offers 
a unique ability to investigate in vivo DA function in awake humans, as well as allowing 
for comparison of PET metrics (binding potential; BPND) with subjective self-report and 
behavioral measures.  The first chapter describes the use of [11C]raclopride (RAC) PET 
to examine the baseline striatal DA system in chronic cannabis users.  The results 
support previous findings in similar cohorts, showing that chronic cannabis use is not 
associated with lower striatal D2/D3 receptor availability, unlike reports for several other 
drugs of abuse.  Urine levels of THC and THC metabolites were correlated with self-
report of recent cannabis consumption, confirming that urine metabolite levels can 
provide an accurate estimate of recent use.  Unexpectedly, both urine THC and THC 
metabolite levels, as well as self-reported recent use, were significantly negatively 
associated with RAC BPND in the bilateral dorsal putamen.  This is the first evidence to 
link magnitude of recent substance abuse of any drug with D2 receptor availability.  The 
association between striatal D2/D3 receptor availability and recent cannabis consumption 
was preliminarily interpreted as a result of smoking-induced monoamine oxidase (MAO) 
inhibition.  Overall, the results reported in Chapter 1 support previous literature in 
cannabis users suggesting that the relationship between cannabis abuse and D2 
receptor availability is different from that of other drugs of abuse.  The prevalence of 
cannabis abuse and dependence is rising, and these findings may have treatment-
relative applications.  That chronic cannabis abuse appeared to affect the DA system 
differently than other abused drugs indicates that perhaps different therapeutic strategies 
should be employed to treat individuals suffering from cannabis dependence.  Further 
studies are necessary to explore the relationship between baseline DA state and recent 
cannabis consumption. 
 The second chapter of this report describes a retrospective analysis of baseline 
striatal D2/D3 receptor availability in three distinct groups:  nontreatment-seeking 
alcoholic smokers (NTS-S), social-drinking smokers (SD-S), and social-drinking non-
smokers (SD-NS).  All subjects received a RAC PET scan at rest.  All but seven smoking 
subjects received a transdermal nicotine patch during the scan day to minimize craving.  
The observed results were contrary to our initial hypothesis, such that smokers had 
lower D2/D3 receptor availability compared to non-smokers, regardless of drinking status.  
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SD-NS subjects were significantly younger than smoking subjects.  However, when the 
association of age with RAC BPND was compared for each group separately, there was a 
significant correlation between age and striatal BPND only in the NTS-S group.  Because 
there was a significant group*age interaction, the use of age as a covariate across all 
groups was deemed invalid (see Chapter 2 Discussion, p. 47).  The significant negative 
association of age with striatal BPND only in NTS-S subjects is potentially of interest.  
This suggests that age-related reduction of D2 receptors associated with normal aging 
may be accelerated in a population of alcohol and tobacco-abusing individuals.  Further 
studies are needed to determine whether comorbid alcohol and tobacco abuse might 
exacerbate normal age-related decline of striatal D2/D3 receptor availability.  In order to 
determine what effects, if any, nicotine patch administration had on striatal BPND, one-
way ANOVA was utilized to detect differences in striatal BPND between three subsets of 
smokers, matched for age and drinking status:  smokers who did not receive a nicotine 
patch during scan day, smokers who received a patch dose of 7mg or 14mg nicotine, 
and those who received a patch dose of 21mg nicotine.  There were no main effects of 
patch dose on striatal BPND, indicating a negligible effect of nicotine patch on our 
reported striatal BPND values.  Additionally, in line with previous reports in alcoholics, 
NTS-S subjects exhibited significantly lower striatal volumes than social-drinking groups.  
However, because RAC BPND was not different between NTS-S and SD-S groups, we 
concluded that striatal atrophy in NTS-S subjects did not significantly contribute to group 
differences in BPND.  Overall, the results from this study suggest that some non-nicotine 
component(s) of cigarette smoke may act on the DA system independently of alcohol 
abuse.  We interpret the association of reduced BPND in smokers compared to non-
smokers as evidence of smoking-induced inhibition of MAO, which results in increased 
tonic DA levels.  Further studies are needed to address the molecular ramifications of 
chronic cigarette abuse on the DA system.       
 The final chapter of this document describes a pilot study to determine if changes 
in cortical DA induced by response inhibition task can be detected by [18F]fallypride 
(FAL) PET.  Nine healthy, social-drinking males received two FAL scans on separate 
days.  One scan was conducted during performance of a “Go” control task, and the other 
was conducted during performance of a stop signal task (SST).  This task assesses the 
ability to withhold a prepotent motor response, which is indexed by stop signal reaction 
time (SSRT).  SSRT is defined as the time required to withdraw (Stop) a ballistic hand 
movement.  Parametric BPND images were generated using the Logan graphical 
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technique.  BPND and images for the separate “Go” and SST conditions were compared 
to determine regions that exhibited changes in DA during the SST task compared to the 
control “Go” task.  The results indicate that SST performance induced changes in DA in 
several cortical regions.  The regions in which SST-induced DA changes were observed 
correspond well to neural correlates of inhibiting an ongoing motor response that have 
been identified by human fMRI studies.  Additionally, we explored an association 
between ∆BPND in cortical regions that exhibited significant SST-induced changes in DA, 
and SST performance (SSRT).  ∆BPND in the left orbitofrontal gyrus, right middle frontal 
gyrus, and right precentral gyrus was negatively correlated with SSRT.  These results 
indicate that DA may be important for modulating activity in these regions during 
performance of a response inhibition task.  Overall, the results presented in Chapter 3 
demonstrate the feasibility of utilizing FAL PET to detect cortical DA changes during a 
SST challenge.  This provides an important foundation for using SST to investigate 
DAergic contributions to disorders characterized by impulsive behavior, such as 
addiction.        
 In summary, this report details the use of DAergic PET to characterize the DA 
system in addiction.  PET imaging, along with DAergic ligands such as RAC and FAL, is 
a useful tool for probing both the DA system at baseline or “rest” (Chapters 1 and 2), as 
well as the DAergic response to a challenge condition (Chapter 3).  In Chapters 1 and 2, 
we used PET and the D2/D3 antagonist RAC to show that recent cannabis consumption 
and tobacco-smoking are both associated with reduced D2/D3 receptor availability.  We 
tentatively interpret these effects as evidence of smoking-induced inhibition of MAO in 
the brain, leading to subsequent elevations of DA.  These effects appear to be 
independent of the pharmacological actions of THC and nicotine alone.  Given the 
extreme prevalence of tobacco smoking among populations of currently using and 
rehabilitated addicts, these results have important implications for clinical treatment of 
any kind of addiction associated with comorbid tobacco use.  Perhaps concurrent 
treatment for tobacco abuse might improve treatment outcome for other disorders.  
Furthermore, in agreement with our results, nicotine replacement therapy has limited 
efficacy for tobacco smoking cessation, which could be due to its limited effects on 
striatal DA concentrations.  Future treatment options involving manipulations of striatal 
DA tone could prove effective for treatment of tobacco dependence as well as comorbid 
addictions.  Results from Chapter 3 emphasize the use of an additional PET measure to 
characterize addictive phenotypes:  changes in BPND in response to a cognitive 
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challenge.  The current protocol was carried out in non-addicted, social-drinkers, but it 
serves as a stepping-stone for similar studies to be undertaken in addicted populations.  
Potentially, this has broad treatment applications, as it could be used to identify neural 
loci where DA signaling during response inhibition is dysfunctional in addicts.  Though 
the utility of PET as a diagnostic tool for addictions is presently impractical, the current 
results underscore the relevance of PET imaging as a tool for characterizing the DA 
system in addiction.     
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Future Directions 
 
 Results from the current report have yielded a great deal of novel information 
about the DA system in human addiction.  Additionally, they establish a basis on which 
new research questions can be interrogated.  One such research question I would like to 
further explore is how DA levels are modulated by tobacco smoke.  Based on results in 
the current document, we suggest that smoking-induced inhibition of MAO is responsible 
for the lower RAC BPND observed in our smoking cohorts.  However, without gathering 
additional data, this interpretation remains speculative.  To further investigate this issue, 
I propose additional analyses in a separate sample of tobacco smokers.  Briefly, a group 
of tobacco smokers would be given one RAC scan at rest, as previously described.  
Urine and blood samples would be collected during the scan day.  Urine nicotine and 
cotinine concentrations would be quantified in order to estimate recent tobacco 
consumption, which would be assessed for agreement with self-report.  Platelet MAO 
activity would be assayed to determine the extent of inhibition (Murphy, 1976).  If 
smoking-induced inhibition of MAO is responsible for elevated striatal DA 
concentrations, then I would expect MAO activity to be positively correlated with striatal 
BPND.  This finding would lend credence to the hypothesis that low striatal RAC BPND 
observed in our smokers is directly related to smoking-induced MAO inhibition.  
However, the absence of such a relationship would not preclude validation of the 
hypothesis.  There is evidence to suggest that brain MAO occupancy may not be 
correlated with platelet MAO activity in certain circumstances [(Fowler, 2003; Young, 
1986), although see (Bench, 1991)], and this would confound results from the proposed 
study.  One way to conclusively determine brain MAO activity would be to conduct 
additional PET scans with MAO radiotracers [11C]clorgyline and [11C]deprenyl-D2 to 
estimate activities of MAO-A and MAO-B, respectively.  However, the excessive cost of 
this analysis would likely be prohibitive.  Alternatively, a genetic component could be 
explored.  Recently, MAO-A polymorphisms that produce “high-” and “low-function” 
alleles have been associated with antisocial behavior, impulsivity, and other 
neuropsychiatric disorders (Craig, 2007).  It would be interesting to see if a genetic trait 
associated with behavioral disorders is correlated with DA receptor availability.  Although 
there is likely a disconnect between MAO-A genotype and brain MAO-A activity (Fowler, 
2007), recent evidence suggests that methylation patterns of the MAOA gene promoter 
can predict brain MAO-A activity (Shumay, 2012).  Information about the relationship 
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between MAO activity and striatal D2/D3 receptor availability would benefit studies of 
tobacco, alcohol, and illicit drug use disorders, as well as other neuropsychiatric 
disorders.        
 An additional research area I would like to further explore is the apparently 
accelerated rate of D2 receptor decline in co-abusers of alcohol and tobacco (Chapter 2 
discussion).  If the heavy co-abuse of alcohol and tobacco is related to an exacerbation 
of the age-related decline of D2 availability associated with normal aging, this could have 
broad clinical implications, as it would suggest an interaction effect of alcohol and 
tobacco on the DA system over time.  With careful recruitment, this question could be 
addressed concomitantly with the previously proposed analysis of RAC PET in the same 
cohort of smokers.  An additional group of non-smoking alcoholics would be necessary 
in order to parse the effects of chronic alcohol drinking alone, without comorbid tobacco 
abuse.  It would also be important to enroll subjects with a sufficient age range to better 
be able to detect an age effect on RAC BPND.  Regression analyses would be performed 
between age and striatal BPND for each group, using the ten anatomically-defined striatal 
regions previously discussed (Chapters 1-2).  Because the normal age-related decline of 
D2 receptors is well documented, I would expect significantly negative regressions 
between age and D2/D3 receptor availability in all groups.  If indeed there is an 
interaction effect between chronic alcohol and tobacco abuse on the DA system, I would 
expect the slope from the regression of age with striatal RAC BPND to be significantly 
steeper than regression slopes from the other groups.  It is possible that this analysis 
would not detect a significant difference between regression slopes.  In that event, I 
would conduct a principal components analysis in an attempt to identify striatal networks 
whose BPND values were collinearly associated with age.  This would identify striatal 
regions whose BPND values were similarly affected by age, and may grant us additional 
power to detect main effects of group.  Because the effect of age on striatal D2 receptor 
availability is heterogeneous across striatal regions (Ishibashi, 2009; Kim, 2011), this 
type of analysis might yield novel relationships between striatal subregions that are 
affected similarly by alcohol and tobacco co-abuse.  Additionally, it would be interesting 
to also compare rates of age-related decline of extrastriatal D2 receptors with 
[18F]fallypride PET.  Similar to well-documented age-related reductions in striatal D2 
availability, cortical D2 receptor availability is also subject to reductions over time (Inoue, 
2001; Kaasinen, 2000).  Interestingly, there is preliminary evidence suggesting that age-
related decline of extrastriatal D2 availability is accelerated in alcoholic subjects 
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(Rominger, 2012a), although the individual effects of alcohol and tobacco use could not 
be discerned by the study design.  The potentially separable effects of alcohol and 
tobacco on age-related D2 reductions could be investigated by inclusion of a group of 
non-smoking alcoholic subjects, or a group of non-drinking smokers without a past 
history of alcohol or substance abuse.  Knowledge of the striatal and extrastriatal regions 
that are most sensitive to alcohol and tobacco-enhanced D2 decline would be helpful to 
identify those regions, and potentially, individuals, that are most at risk for damage due 
to chronic use of alcohol and tobacco.          
 One final research question I would like to ask is:  what are the neural correlates 
of response inhibition in alcoholics, and how do they differ from social drinkers?  To 
answer this, I would conduct a FAL PET study similar to the one described in Chapter 3.  
Briefly, the study would include a group of nontreatment-seeking alcoholics and a group 
of social-drinking controls, matched for age, sex, and smoking status.  Subjects would 
receive two FAL scans on separate days, one during a “Go” control task and one during 
a SST.  Scans would be acquired for 180 minutes in order to accurately estimate striatal 
BPND with FAL.  The data would then be analyzed to detect group differences in SST-
induced DA release.  If results from the control subjects in the proposed study replicated 
the results presented in Chapter 3, this would greatly strengthen the validity of the 
results presented here.  Evidence of group differences in SST-induced DA release would 
be helpful in identifying the neural locus of impaired impulsive control in alcoholics.  
Going further, it would be of interest to compare changes in FAL BPND between scan 
conditions to measures derived from an additional imaging modality.  One imaging 
technique that could be employed is diffusion tensor imaging (DTI).  DTI has identified 
TBI-associated reductions in white matter tract integrity (indexed by fractional 
anisotropy) that correlated with SST performance (Bonnelle, 2012).  Resting state fMRI 
(RS-fMRI) is another potentially applicable modality.  RS-fMRI signals in the IFC and 
default mode network hubs are predictive of SST performance (Tian, 2012).  In 
conjunction with FAL PET, DTI and RS-fMRI could provide novel information about how 
differences in structural connections can regulate DA signaling during a motor inhibition 
task. 
 Results from the current report have provided important information about DA 
function in addiction and addictive phenotypes.  However, further studies are necessary 
to both validate the present data, as well as address questions that have arisen from our 
interpretation of the data.                    
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